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Scanning kelvin probe microscopy has been to used to understand the operation of, and
optimize the performance of both organic and inorganic photovolataic materials on the 10’s
of nm scale. Most studies have only examined the spatial distribution of the electronic
phenomena – including potential, photopotential, capacitance, photocapacitance, current,
and photocurrent – however, there is much to be learned by measuring and mapping the
time-dependence of these characteristics. In organic bulk heterojunction solar cells, Ginger
and coworkers have shown by time-resolved electrostatic force microscopy (tr-EFM) that the
microscopic photocapacitance charging rate in a film is directly proportional to the external
quantum efficiency (EQE) of a photovoltaic device. Transients with sub-microsecond time
resolution have been collected, but acquiring these transients required long signal-averaging
times. Building on the previous work of Moore, Marohn, and co-workers, we developed a
method to rapidly acquire transients of capacitance, frequency and phase indirectly, in a
stepped-time, stepped-voltage experiment, by encoding and measuring the capacitance as
a change in the phase of a vibrating cantilever. In a proof-of-concept experiment we show
that this new method is viable for observing transients down to 100 µsec. This approach
represents an exciting new route to understanding geminate recombination in photovoltaic
materials.
Mitochondrial calcium plays a critical role in regulating cell survival, apoptotic pathways,
and cellular energetics. Acute overload of mitochondrial calcium will induce cell death and
is implicated in the damage caused by lethal reperfusion injury. Inhibitors of mitochondrial
calcium uptake minimize the harm caused by such conditions. The most well character-
ized mitochondrial calcium uptake inhibitor is Ru360, a µ-oxo-bridged dinuclear ruthenium
complex. Its synthesis and purification is challenged by extremely low yielding reactions
and purification by tedious cation exchange chromatography. Furthermore, this compound
is not cell permeable, a feature that significantly limits its biological use. With the goal
of preparing potent mitochondrial calcium uptake inhibitors that are biologically available,
we investigated the synthesis and characterization of six dinuclear ruthenium species. One
complex is a structural analog of Ru360, and five are structurally similar dinuclear ruthe-
nium µ-nitrido complexes. These compounds were characterized by NMR spectroscopy, EPR
spectroscopy, UV-vis spectroscopy, infrared spectroscopy, cyclic voltammetry, conductivity,
and small-molecule crystallography. Mitochondrial calcium uptake inhibitory activity in
permeabilized and unpermeabilized cells are described. Cellular uptake of the complexes
and cytotoxicity are presented and discussed in the context of molecular structure. One of
these complexes shows 10× better MCU-inhibitory activity, low cytotoxicity, and enhanced
cellular uptake compared to Ru360.
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CHAPTER 1
PROOF-OF-CONCEPT EXPERIMENTS ON MICROSECOND CHARGING
TRANSIENTS VIA SCANNING KELVIN PROBE MICROSCOPY
1.1 Introduction
When a solar cell is irradiated, charge is generated and thus electrical current. The dy-
namics of charge generation is a subject of ongoing research to new photovoltaic materials.
The motivation for this work is to couple the high spatial resolution of scanned probe mi-
croscopy with local temporal information to understand the spatially-dependent dynamics
of a solar-cell material. The focus for this discussion is organic-based photovoltaics, however
temporal related studies of materials are universally relevant.
Organic-based photovoltaics use conjugated small molecules and polymers to convert
photons into free charges. The blend of two or more polymers will form a bulk heterojunction
(BHJ) film.1–4 One of the polymers acts an electron donor, or n-type material, while the other
is the electron acceptor, or p-type material; the interface of the two materials forms a junction
at which charge is generated.5–7 In general even simple blended systems are advantageous
because they have a many junctions, and can easily be prepared and studied.1,8–12 Organic-
based photovoltaic systems are useful because their properties can be tuned via a plethora of
synthetic and processing methods.13 These types of solar cells have developed significantly
over recent years, with the highest efficiency device to date reported at 11-12%, compared to
crystalline silicon at 28%.14–16 A variety of factors can affect device performance including
composition, polymer molecular weight, thickness, and annealing.17–26 In contrast to silicon
solar cells that produce charge immediately upon irradiation, light absorption in organic
photovoltaics forms neutral excitons. Upon migration to a junction, the exciton splits into
an electron and hole.10,13,27 Any recombination between the electrons and holes, as well
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as the mobility of the exciton and the generated charges, will affect the overall efficiency
of the device. Additionally, the aforementioned factors will also affect these microscopic
phenomena.9,25,26,28–30
Upon photogeneration of excitons and thus charge carriers in a film (or device), sev-
eral fates are possible. The charges can be “trapped”, effectively not going anywhere for a
time; they can diffuse and be extracted; or they can recombine producing heat or light.13
Recombination represents, effectively, nonproductive work; typical time constants range for
recombination in the hundreds of nanoseconds to microseconds.30–33 The rate at which these
processes happen is highly variable, largely dependent on device composition.9,25,34–37 Many
devices have an almost 100% internal quantum efficiency, or how well the incident photons
produce charge (photon-to-charge-carrier yield). However, these devices often have an ex-
tremely low power-conversion efficiencies.38,39 This dichotomy is puzzling as it reveals that
a number of the charges produced are not contributing to device current. Understanding
the fate of the generated excitons, electrons, and holes will provide information about the
physical mechanisms controlling device efficacies. Thus, studies of the dynamics of these sys-
tems on the nanosecond to microsecond time scale, with high spatial resolution, will provide
understanding to the governing limitations and processes.
To assess phenomena such as charge carrier generation, mobility, and recombination,
in the time-domain a variety of time-dependent instrumental techniques have been de-
veloped, including transient absorption spectroscopy, time-resolved photoluminescence and
time-resolved microwave conductivity.13 Briefly, transient absorption spectroscopy probes
the absorption of photons over time in a thin film. The change in absorption is stimulated
by an ultrafast laser and measured over time. This technique has a wide temporal range,
with examples ranging from picoseconds to microseconds.25,27,28,30,34,40–43 The observed time-
dependent absorption spectrum provides information about crystallinity, annealing effects,
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photogeneration, and recombination. However, the technique is not spatially resolved and
spectral features can be complicated by overlapping absorption bands.27 Time-resolved pho-
toluminescence tracks the decay in luminescence after stimulation of the sample with a laser
pulse. Typically this technique probes time scales between picoseconds to nanoseconds.29,37,44
The decay is generally associated with the radiative decay of charge-transfer states within an
organic polymer film.4,9,29,37,45–48 While photoluminescence measurements can be spatially re-
solved, scanned probe microscopy has ∼100-fold better spatial resolution.49–55 Time-resolved
microwave conductivity (TRMC) has been used to study trapping and recombination in
photoactive samples in the nanosecond to second time regime.16,35,36,44,56 The formation
of charge-transfer excitons in these films typically occurs on the femtosecond time scale,
however charge generation, recombination, and trapping and detrapping times are orders
of magnitude slower and more directly effect device performance. Microwave conductivity,
as a general technique, measures the mobility of charges in a sample (specifically the free
carriers’ mobility-charge density product). As mobile charges are generated they interact
with the electric field of the incident microwaves.16,57 The resulting change in transmitted
or reflected power reveals information about the nature of the charges and their lifetimes.
However, the technique cannot distinguish between positive and negative charges and no
spatial information can be obtained.
Scanning Kelvin probe force microscopy (SKPFM), or electrostatic force microscopy
(EFM), is a scanned probe technique similar to atomic force microscopy (AFM); it measures
the forces between charges (for EFM) within the sample and a charged microcantilever rather
than the neutral van der Waals forces (for AFM) between two close objects.58–64 It can be
used to measure the surface potential of a material, to visualize trapped charge locations, or
to investigate the kinetics of charging or trapping on a surface65,66. EFM/SKPFM1 provides
a method to visualize charge at high spatial resolution – 10s of nanometers.66 Time-resolved
1For the rest of this discussion EFM will be used for simplicity
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EFM has been explored, but only in a limited sense. One report used photoluminescence to
show the photogenerated exciton in highly-ordered closely-linked quantum dot arrays was
quenched on the nanosecond time regime; EFM indicated that free charge was still present
for seconds.67 Application of time-resolved EFM to a polymer blend photovoltaic showed
that the rate of charging in a film prepared without a top contact correlated well with the
device external quantum efficiency (the ratio of charge carriers produced to photons absorbed
in a complete device), as well as overall device efficiency.68 These experiments tracked the
photo-induced change in the cantilever frequency and obtained millisecond time resolution.
Further experiments increased the time resolution down to ∼100 nanoseconds, where directly
tracking the frequency change required a high number of scan averages.69,70 A 2D scan of
a polymer blend films showed, on average, a sub-30 microsecond charging rate with gener-
ally high spatial uniformity. This method is slow, and is limited by the inverse relationship
between time resolution and photodetector bandwidth (tr = 1/bw), thus requiring excessive
averaging times, as explained below (∼ 14 h for single nanosecond resolution). Other types
of KPFM methods have been used to measure change down to the picosecond time regime,
however these exploit the nonlinear dependence of the photovoltage on light intensity and
or the cantilever frequency.71–75 However, these methods are less applicable to organic donor
acceptor blends as the photocapacitance between the tip and the sample is linearly depen-
dent on the light intensity.76 We propose to utilize an alternative method to determine rate
of charge carrier generation on the microseconds time scale with high spatial resolution and
low signal averaging times using EFM.
1.2 Theory
In EFM, an extremely sensitive oscillating cantilever is brought close to the sample surface
with a bias applied to the tip or the sample (Figure 1.1). The oscillating microcantilever
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can be modeled as a damped driven harmonic oscillator with a corresponding frequency,
phase, and amplitude. Over a surface, the tip and sample charge to first approximation can
be modeled as a parallel plate capacitor. Corrections for the conical shape are possible if a
more exact tip-charge estimate is desired.77–79
Figure 1.1: Setup for time-resolved electrostatic force microscopy over a simple gold sample.
A perturbation in the interaction between the oscillating cantilever and the sample will
subsequently result in a change in the phase and frequency of the cantilever oscillation (Figure
1.2).58,63,68,69 Any change in the sample charge will produce a change in the tip-sample
capacitance, as well as the first and second height derivative of this capacitance (Equation
1.1). The frequency (f ) can be related to the cantilever tip voltage (Vtip), the unperturbed
cantilever frequency (f0), the cantilever spring constant (k), the surface potential of the
sample (φ(x)) and the capacitance second height derivative (C ′′).63,79
f(V ) ' f0 − f0
4k
C ′′(Vtip − φ(x))2 (1.1)
The resulting frequency shift of the cantilever is related to the charge dynamics in the
sample: a time-dependent change in the charge state of the sample or tip (C ′′, Vtip or φ(x))
will change the time-dependent cantilever frequency. The cantilever oscillation traces out
a sine wave; the instantaneous frequency and phase can be determined via mathematical
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demodulation of the displacement versus time data.80 The steady-state motion of a driven,
oscillating cantilever has the form
y(t) = Asin(φ(t)). (1.2)
Demodulation of the cantilever position oscillation data will yield the time dependent phase,
φ(t), frequency, f(t) and amplitude, A(t). Experimentally, the position y is measured versus
time, t. Via signal demodulation, a signal processing method of finding the phase and
frequency from the analytic signal, z(t), the desired A, φ, and f can be found as a function
of time. The analytic signal is defined as
z(t) = y(t) + iH[y(t)] (1.3a)
= a(t)eiφ(t) (1.3b)
where H[y(t)] is the Hilbert transform, and a(t) is the time dependent amplitude.81,82 There-
fore, the amplitude is the argument of z(t) and the phase is the angle of z(t) (Equation
1.3b).80 Functionally, this process is done by (1) taking the Fourier transform of the posi-
tion data and baseline correcting it, (2) inverting the negative frequency components in the
Fourier domain, (3) adding (1) and (2) together to effectively zero the negative frequency
portions and double the positive frequency components, and (4) taking the inverse Fourier
transform, revealing the time-dependent phase and time-dependent amplitude.81,82 The fre-
quency is defined as the time derivative of phase and thus can be calculated as follows:
φ(t) = 2pi
∫ t
0
f(t′)dt′ + φ0. (1.4a)
f(t) =
1
2pi
∂φ
∂t
(1.4b)
As such, the area under a time-dependent frequency trace is equivalent to the phase. If
the change in photocapacitane is controlled by a time constant (τ), then the frequency and
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phase must also contain that same information. Using
f = ∆fe−t/τ
as an example for the frequency we obtain
φ = 2pi∆fτ(1− e−t/τ )
via equation 1.4b.68,69 We seen then that τ , the the photocapacitance lifetime associated
with a single process, can be determined from the phase or the frequency.
Determining τ via a phase or frequency transient will produce identical values, how-
ever the experimental noise will be different. The main contributors for cantilever noise at
low frequencies (<100 Hz) is thermal noise and at high frequencies (>1000 Hz) is detector
noise.81 The detector noise increases quadratically with frequency. Consequently fast time
experiment (which incorporate noise covering a large bandwidth) will inherently have a lot
of noise. The application of a filter will reduce noise levels, however, the associated filter
bandwidth (bw) will stipulate the time resolution (tr) (bw = 1/tr). Therefore the analysis
of data on short time scales will require very large bandwidths: for example, microsecond
time resolution will require a bandwidth of 1 MHz. To determine how the frequency noise
scales with bandwidth we look at the power spectrum of position fluctuations (P detδx ) and the
power spectrum of frequency fluctuations (Pδf (f)), starting with the rms position (δx
2
rms).
Integrating across frequency determines the rms frequency noise.
Pδf (f) w
P detδx
x2rms
f 2 (1.5a)
δf 2rms =
∫ bw
−bw
P detδx
x2rms
f 2df (1.5b)
⇒ δf 2rms =
P detδx
x2rms
1
12
bw3 (1.5c)
∴ δfrms ∼ bw3/2 (1.5d)
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The rms frequency noise has a 3/2 power dependence on the bandwidth and thus a 3/2
power dependence on the time resolution. In comparison, the bandwidth dependence on the
phase noise is significantly less. An analogous integration gives the rms phase noise.
Pδφ(f) =
Pδf (f)
x2rms
(1.6a)
δφ2rms = 2pi
∫ bw
−bw
P detδx
x2rms
df (1.6b)
⇒ δφ2rms = 4pi
P detδx
x2rms
bw (1.6c)
∴ δφrms ∼ bw1/2 (1.6d)
This analysis reveals that the rms phase noise has only a square root dependence on the
bandwidth instead of a 3/2 dependence, thus a 1/2 power dependence on time resolution.
The common solution to the high frequency noise problem is signal averaging for frus-
tratingly long times. However, by converting the photocapacitance transient experiment to
a phase measurement we can exploit the noise difference and obtain more time resolution
with less signal averaging.69,83 The change in sample capacitance upon photoirradiation can
be modeled as an exponential rise and decay (instead of a single τ as illustrated above),
with time constants associated with each portion (τr and τd, respectively), (Figure 1.2a).
According to Equation 1.1, the change in frequency will also rise and decay; the rate of
photo-capacitance change can be measured by tracking the cantilever frequency shift over
an illuminated sample (Figure 1.2b). The frequency will track with the capacitance linearly
in the experiment, with both τr and τd accessible. However considering both of these simul-
taneously is more complex as the generation of charge (exciton splitting) most likely does
not occur at the same rate as de-charging (recombination, trapping). To access only a single
time constant, only the frequency shift for the rise (or decay) is desired. This selection can
be done by applying a voltage to the cantilever tip: the frequency shift can be returned to
zero (Equation 1.7, Figure 1.2c). By varying the length of time (tp) the cantilever tip is
biased, the length of time the frequency shift evolves can be varied in a systematic way.
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The photo-induced of the frequency transient effectively causes a shift in the cantilever
phase, where the shift is equal to ∆φ (Figure 1.2d). By varying the voltage pulse time (tp),
we vary the length of time that frequency transient occurs and therefore also the size of
the phase shift (∆φ). Integrating each portion of the frequency transient, equation 1.7, and
adding the two pieces together produces an equation for the phase shift which depends on
τr, pulse time (tp) and the steady state frequency shift (δfss) (Equation 1.8). The steady
state frequency shift is equal to the maximum shift when the transient rises to its steady
state value.
f(t) = δfss

1− e−t/τr t ∈ (0, tp)
0 t ∈ (tp,∞)
(1.7)
∆φ = δfss((e
−tp/τr − 1)τ + tp) (1.8)
In equation 1.8 at short times the exponential term dominates, while at long times the linear
term dominates.
1.3 Methods
All experiments were performed under vacuum (8×10−7 mbar) in a custom-built scanning
Kelvin probe microscope.59 The cantilever (MikroMasch HQ:NSC18/Pt conductive probe)
had resonance frequency f0 = 62,000 kHz, spring constant k0 = 6.9 N m
−1, and quality factor
Q = 32,000. Cantilever motion was detected using a fiber interferometer operating at 1310
nm (Corning SMF-28 fiber). The laser diode’s (QPhotonics laser diode QFLD1490-1490-5S)
dc current was set using a precision current source (ILX Lightwave LDX-3620), and the
current was modulated at radio frequencies using the input on the laser diode mount (ILX
Lightwave LDM 4984, temperature-controlled with ILX Lightwave LDT-5910B).84 The in-
terferometer light was detected with a 200-kHz bandwidth photodetector (New Focus model
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2011, built-in high-pass filter set to 300 Hz) and digitized at 1.25 MHz (National Instru-
ments, PCI-6259). The cantilever was driven using a commercial PLL cantilever controller
(RHK Technology, PLLPro2 Universal AFM controller), with PLL loop bandwidth of 1.2
kHz (PLL feedback loop integral gain I = 2.5 Hz−1, proportional gain P = -12°/Hz).
At the beginning of the experiment the cantilever tip was biased at 6 V, to achieve
linearity between the frequency shift and applied voltage.63 The frequency shift is dependent
on the capacitance change (Figure 1.2a, Equation 1.1). For a proof-of-concept experiment,
instead of illuminating a photoactive sample, a single voltage pulse of known duration and
shape following Equation 1.7 was applied to a 200 nm gold sample on silicon 2 (240 nm
tip-sample height). The cantilever tip remained biased through the whole experiment to
achieve the desired linear relationship between the size of the voltage pulse and the frequency
shift. The voltage pulse was stepped (tpulse) as shown in Figure 1.2c. The data acquisition
was triggered on a rising zero crossing of the cantilever oscillation using the square wave
copy of the cantilever signal. After acquiring 50 ms of data, a voltage pulse was triggered,
starting on the rising edge of the square wave copy of the cantilever signal. The voltage
pulse was returned to zero after the transient developed for tpulse (Figure 1.2b, Equation
1.7). The experiment was then repeated while varying the time that the frequency (and thus
phase) shift accumulates. The data was processed in Python using the demodulation scheme
outlined above. The demodulation bandwidth was set at the minimum possible as to not
introduce unnecessary noise. For example, for a one millisecond time constant, a bandwidth
of one kilohertz was used. The filter utilized was based on the Blackman filter with minor
modifications:
b(n) = 0.42− 0.50 cos(2pin
bw
) + 0.08 cos(
4pin
bw
). (1.9)
The edges of the filter were set to zero to ensure that no artifacts were introduced.
2Thanks to Pamela Nasr for preparing the samples.
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(a) (b)
(c) (d)
Figure 1.2: (a) The model of the second derivative of the cantilever rising and decaying with
different time constants. (b) The frequency change observed as the result of multiplying the
tip voltage (c) and the modeled capacitive change (a). (c) The modulation of the tip voltage
to access each piece of the changing capacitive. (d) The phase jump associated with a single
frequency trace, equivalent to the area under the frequency transient. As the tip voltage is
stepped in time, the frequency transient increases, and the phase jump also increases.
.
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To determine ∆φ, five milliseconds of the phase data was fitted directly before and after
after the pulse. The experiment was repeated sixteen times for each pulse time, with a total
of ten milliseconds of data for the workup of each pulse. The linear portions are extrapolated
to a common time and the phase shift difference determined (Figure 1.2d). The phase shift
will be different for each pulse length and will follow equation 1.8. The trace of phase shift
versus pulse time was then fitted to determine τr. The data was fitted using MagicPlot Pro
v. 2.7.2.
1.4 Results and discussion
The phase shift exhibited a sub-linear dependence on pulse time, as expected from equa-
tion 1.8. At short times the exponential portion could be observed while at longer times
the rise was largely linear. Fitting successfully obtained the known time constant τr of the
applied voltage pulse (Table 1.1, Figure 1.3). In each case the applied transient could be
redetermined from the fit, within 2σ error bars. A ringing in the phase was observed af-
ter the phase shift with an oscillating frequency of 400 Hz, equal to the bandwidth of the
positive feedback circuit used to drive the cantilever; while not applied to this experiment,
turning off the cantilever drive just before the voltage pulse would remove this artifact.76 A
slow oscillation could be seen in the 800 µsec data (Figure 1.3d); this is attributed to slow
drifting in the phase over the time span of the voltage pulse. Removing the last (longest tp)
five data points greatly improves the fit of the data (see 800b entry).
12
Applied τr (µsec) Calculated τr (µsec) δfss (Hz)
100 73 ± 35 0.56 ± 0.017
250 282 ± 34.0 0.50 ± 0.0066
400 429 ± 78.0 0.25 ± 0.0054
800a 715 ± 85.0 0.31 ± 0.0037
800b 811 ± 57.0 (1σ) 0.33 ± 0.0063
Table 1.1: The fitted results for δfss and τ compared to the τ of the voltage applied. For
800 µsec, the removal of the last five data points greatly enhanced the quality of the fit.
The theory derived here assumes the sample is is evolving only under a single time con-
stant, although the same experiment could be performed with a biexponential capacitance.76
This analysis may be more realistic to donor-acceptor blend dynamics, as they frequently
show complex time evolution.
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(a) (b)
(c) (d)
Figure 1.3: Raw data with fits (Table 1.1) for four different applied time constants with
residuals shown for each.
1.5 Conclusion
A proven way to observe capacitance transients in a sample is by tracking the frequency
shift of a cantilever in real time. However, this method introduces increasing amounts of noise
with increasingly fast transients. By exploiting the inherent relationship between frequency
and phase it is possible to observe the net effect of a capacitance transient on a sample in
cantilever phase. The new method does not rely on watching the transient in real time, as
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with frequency, but instead is observed after the transient has occurred. By stepping the
length of time the cantilever voltage is applied to the tip the “amount” of frequency transient
evolved is also stepped. This resulting frequency step is associated with corresponding shift
in the phase containing the same information as the frequency transient. As the length of the
tip voltage is moved forward the phase transient is measured. Thus, the frequency transient
is also determined.
As a proof-of-concept experiment voltage pulses were applied to a conductive sample
to induce a frequency shift and phase jump in an oscillating microcantilever. The voltage
pulses contained an exponential rise; the relationship between the time length of the pulse,
tp and the phase jump, ∆φ, was derived. For each ∆φ vs tp plot the time constant (τr)
was determined to be within error of what was applied. Further experiments employed the
phase-kick technique introduced here to model donor/acceptor blends, as well as exploring
the time resolution limits of the technique.76
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CHAPTER 2
INTRODUCTION TO MITOCHONDRIAL CALCIUM AND INHIBITORS
2.1 Mitochondrial calcium
Calcium (Ca2+) is a critical ion that regulates cellular homeostasis by mediating cellular
signaling, electrochemical gradients, and cell death processes. As such, the disruption of
proteins that regulate calcium levels, particularly mitochondrial calcium levels, can severely
affect cellular health.85–88 Thus, understanding the affect of mitochondrial calcium levels on
specific pathologies remains an ongoing research objective. Within a cellular environment
metal ions perform critical roles in a variety of functions including cell signaling, electro-
chemical gradients and tonicity within organelles.89–92 Of the biologically relevant metal
ions, calcium ions have been implicated in both diseases and healthy cell processes.88,93–101
The typical concentration of calcium in a healthy mammalian cell is, on average, 100 nM.102
Two organelles are effective buffers for calcium levels: the mitochondria and the endoplas-
mic reticulum.96,103–106 Several transmembrane ion channel proteins have been identified as
concentration-sensitive controls for calcium levels within the mitochondrial matrix. Two
of these, the sodium/calcium exchanger and the mitochondrial calcium uniporter complex,
have received a considerable level of attention and will be discussed in more detail below.
This discussion is relevant as focus of later discussions (Chapters 3-5) are the synthesis,
characterization, and biological activity of new mitochondrial calcium inhibitors.
2.1.1 Methods to measure mitochondrial calcium
To understand calcium levels and flux within the mitochondria and cellular environ-
ments, a number of calcium sensors have been developed. The main methods to measure
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mitochondrial calcium are calcium-sensitive fluorescent probes, such as the rhodamine dyes,
or recombinant expression of calcium-sensitive mitochondrial-localized fluorescent proteins.
Each of these is useful for specific applications, but has limitations for a holistic understand-
ing of calcium movement. The fluorescent dyes are the most commonly utilized, due to
general ease of use and the extensive use of confocal microscopy.107,108
(a) (b)
Figure 2.1: a) The structure of Rhod-2 AM in the cell-permeable acetoxymethyl (AM)
ester form. The ester is cleaved intracellularly (greyed portion) which renders the dye cell-
impermeable. b) The structure of Calcium Green-5N in the cell-impermeable, hexapotassium
salt form.
The most common mitochondria-targeted fluorescent dye is rhod-2, which contains a
positively charged imine (Figure 2.1a).109–113 In the acetoxymethyl (AM) ester form, the
dye will be taken into cells. The positively charge imine targets the dye to the mitochon-
drial matrix due to the electrochemical gradient existing across the inner mitochondrial
membrane.108,114 The esters will then be cleaved by mitochondrial esterases, rendering the
dye impermeant and trapping it inside the mitochondria.108,114,115 The BAPTA (1,2-bis(o-
aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid) group forms the calcium binding moiety;
subtle changes on this moiety will change the binding constant significantly. In the presence
of calcium ions, rhod-2 will increase in fluorescence; it has a binding constant (Kd) for cal-
cium of 570 nM.109,110,116 Several additional analogs of Rhod-2 have been developed, tuning
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the binding constant between 570 nM and 320 µM.
Many different molecular probes have been developed for calcium imaging in the cy-
tosol.109,112,116,117 By subtle changes in the molecular structure, different binding affinities,
excitation and emissions wavelengths, and quantum yields have been accessed. Fluo-4 is one
of the most common probes, with a Kd of 350 nM.
117 Other probes include the Calcium
Green series, the Calcium Orange series, the Oregon Green series, Fura Red, and Fura-2.116
Many of these are used as probes in confocal microscopy or flow cytometry. However, they
can also be used in cuvette-style assay to assess mitochondrial calcium uptake. In this sys-
tem the cells are incubated with a dye and suspended in a media-like buffer. One of the dyes
commonly used in the these types assays is Calcium Green-5N (Figure 2.1b).111,112,118–120
Calcium Green-5N is a relatively weak binder (Kd = 14 µM), and therefore easily releases
calcium as the mitochondria uptakes the ions. The cell cocktail also typically includes a cell
permeabilization agent, such as digitonin. For mitochondrial assays, permeabilization allows
for the organelle to be relatively directly accessed by calcium boluses and inhibitors. The as-
say, although easy and quick, is highly sensitive to the number of cells - more is better.110,111
This can be a disadvantage for cells that grow very slowly, or are very difficult to culture.
In addition, these types of assays require the cell membrane to be permeabilized, usually
with digitonin. While much information about inhibitors and calcium movement has been
discovered with this experiment, it is not directly relevant to an in vivo system.
The other method to measure calcium levels is utilizing a genetically encoded luminescent
or fluorescent protein.102 These approaches are advantageous due to highly specific organelle
localization via peptide targeting sequences. The aequorin protein, a luminescent protein
isolated from Aequorea victoria is activated by calcium ions and will oxidize the aromatic
substrate coelenterazine.121–123 Using a mitochondrial targeting sequence, this luminescent
probe quickly became an important tool for studying mitochondrial calcium.124,125 Aequorin
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is advantageous because it can be genetically expressed in standard transgenic models, folds
properly in most cell types to form active protein, can be targeted to specific organelles
within a cell, can be modified to accommodate different calcium levels, and circumvents the
autofluorescence background problems found with fluorescent dyes.126–130 However, some
experimental conditions, such as the application of permeabilizing agents, will induce leak-
age of the probe into the cytosol leading to inaccurate data analysis.131 In addition, the
photon production was reported as relatively low, therefore single cell studies were not pos-
sible.110,131 The mitochondria-targeted aqueorin probe is frequently used for studies with the
mitochondrial calcium uniporter in yeast (discussed later).
Genetically encoded fluorescent probes have many of the same advantages as the biolu-
minescent probe aequorin: genetic encoding, organelle targeting and active protein expres-
sion.132–135 These probes have the advantage over the luminescent probes due to the higher
photon output of fluorescence.110 One of the common types used are a cameleon FRET
based systems, which comprise of two fluorescent protein domains joined by the calmodulin
calcium binding moiety.136,137 For example, one side will contain a blue fluorescent protein
(BFP) that excites at 370 nm and emits at 440 nm. In a low calcium environment only
the 440 nm emission will be observed. Upon the addition of calcium, the tertiary structure
changes, and the 440 nm emission will excite a green FP (GFP), emitting now at 510 nm.
Tracking both the emission of the donor (BFP) at 440 nm and the acceptor (GFP) at 510
nm allows for the observation of precise changes in calcium ion concentration.136 Other types
developed include cAMP and GMP probes, pericams, and camgaroo.138–143 Many of these
probes also contain the calmodulin moiety as the calcium binding unit. One potential dis-
advantage would be interference with the cellular calmodulin and its regulatory pathways,
however this has not been significantly prohibitory to application.102,110,111
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2.1.2 The sodium/calcium exchanger
Mitochondrial calcium influx and eﬄux is carefully regulated because of the critical role
that these ions play in the maintenance of the mitochondrial membrane polarization, the
control of cytosolic calcium fluctuations and general cellular homeostatis.86,87,144,145 The mi-
tochondrial sodium calcium lithium exchanger (NCLX) resides in the inner mitochondrial
membrane and is one of several sodium/calcium exchangers discovered. The NCLX is one of
the key proteins implicated in the influx of sodium ions into the mitochondrial matrix and
eﬄux of calcium ions. The mitochondrial NCLX is unique in its ability to also transport
lithium ions.146–154 Several cellular mechanisms are present for the control of calcium and
sodium ion levels in the cytosol and organelles, one of which is the NCLX.149 The ratio of ion
exchange is a subject of investigation; there is evidence for both one Ca2+ for either two or
three Na+. This ion exchange could possibly also play a role in the electrochemical potential
of the cell.155–161 The total charge ratio is 2:3 if a 1:3 ion ratio (electrogenic exchange), but a
charge ratio of 2:2 if a 1:2 ion ratio (electroneutral exchange). Careful studies indicate that
under low cytosolic calcium levels, the NCLX performs the 1:2 Ca2+/Na+ electroneutral
exchange. Additionally, under certain conditions, the direction of ion flux will change. For
example, in myocardial ischemia the lowering of the pH will stimulate the sodium/proton
pump, increasing the amount of sodium outside mitochondria.162 The overload of sodium
ions will reverse the direction of the NCLX, pumping calcium inside and sodium outside.
Upon restoration of the internal pH, the NCLX will return to “normal” operating condi-
tions: pumping calcium outside and sodium inside. At high enough cytosolic Na+ levels, the
protein will saturate, reaching a steady state of Ca2+ eﬄux.152–154,163
The NCLX protein has two different active isoforms, a 70 kDa monomer and a 50 kDa
monomer, isolated both from brain and heart tissue.148 Immunoblot assays also revealed a
∼100 kDa dimer isolated from HEK293 (epithelial kidney cells) mitochondria.150 Based on
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analysis of the crystal structure of a NCLX homolog, there are three Na+ and one Ca2+
binding sites, consistent with studies determining that the protein was electrogenic (Figure
2.2). The structure revelas a membrane bound protein with ten transmembrane domains that
appears as sets of two helices (α1 and α2).154,164,165 The Na+ and Ca2+ binding site regions
are highly conserved through the NCX protein superfamily, and are maintained although
the NCLX was found to diverge evolutionarily relatively early on.149
Figure 2.2: Crystal structure of the sodium calcium exchanger homolog crystallized from
Methanococcus jannaschii. The purple atoms are Na+ and the green atom is Ca2+. PDB
3V5U.164
In cardiac ischemia and reperfusion, the deleterious outcome is substantially caused by
high mitochondrial Ca2+ levels. The controlled eﬄux of Ca2+ is critical to prevent the
formation of the mitochondrial permeability transition pore. The mitochondrial permeability
transition pore is a set of proteins that forms under high calcium ion conditions, and begins
the signal cascade leading to apoptosis. Thus, the balance of the mitochondrial calcium
uniporter and NCLX proteins is critical for ionic homeostatis between the mitochondria and
the cytosol.
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2.1.3 The mitochondrial calcium uniporter complex
The mitochondrial calcium uniporter (MCU) was first posited to explain the observed
regulated increase of calcium ions into the mitochondria.166 However, it was unknown if it
was a single protein, or a set of proteins. The complete mitochondrial protein inventory
(MitoCarta) was determined in 2008.167 This inventory led to the identification of MICU1,
a protein associated with mitochondrial Ca2+ influx.168 Soon afterwards, MICU2, MCUb
and MCU were also identified, with the MCU determined to only be the pore-forming pro-
tein.169–172 MCUb is a paralog of MCU and also assists in regulation, although there is
limited knowledge of the precise function.173,174 The last piece was the EMRE, a small reg-
ulatory subunit that was found to be critical for MCU function and calcium uptake (Figure
2.3).174,175
Although the MCU is the protein that forms the transmembrane pore (Figures 2.4a and
2.4b), the other components are critical for function. MICU1 and MICU2 both contain EF
hand domains (Ca2+ binding domain) and reside in the intermembrane space of the mito-
chondria. Specifically, the EF hand domain in MICU1 was observed in the crystal structure
and was shown to be critical to MCU function.176,177 These two proteins are thought to act as
“gatekeepers” through their association with each other and the MCU – a double knockout
of the MICU1 significantly decreases the mitochondrial calcium influx.174,178–182 The EMRE
is a 10 kDa protein with a predicted transmembrane domain and a mitochondrial targeting
sequence.174 Knockout studies showed that loss of the EMRE had the same effect as loss
of MICU1, suggesting that EMRE mediates interactions between the MCU and MICU1.
Two recent studies indicate that one of the functions of the EMRE is to stabilize the MCU
complex and raise the kinetic barrier to proteolysis.183,184 However, this is not universal as
the EMRE is primarily expressed in metazoa; the regulatory subunits are not necessary for
function of the non-metazoan derived MCU.174 Only the non-metazoan Dictyostelium dis-
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coideum MCU was required for calcium influx, however both the EMRE and MCU were
required for the human homolog.175 Sacharomyces cerevisiae does not have an MCU. This
was taken advantage of to express the MCU and EMRE in S. cerevisiae along with the
mitochondrial-targeted aqueorin luminescent probe. The ability to express this protein sys-
tem in yeast has opened up avenues of research into the mechanisms and inhibitors of the
MCU.185–187
The proteins form a complex residing the inner mitochondrial membrane, with the MICU1
and MICU2 primarily in the intermembrane space (Figure 2.3). The voltage-dependent anion
channel (VDAC) forms the ion pore between the cytosol and the intermembrane space and
allows calcium to pass through uninhibited.188 In low calcium-concentration conditions the
MCU pore will remain closed as little to no calcium ions will be bound to MICU1 and
MICU2. However, under high calcium concentrations the opening of the MCU pore will be
exposed to allow calcium to move into the mitochondrial matrix.87
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Figure 2.3: Schematic of the assembly required for mitochondrial calcium uptake suggested
by Mammucari et al.87
The MCU in C. elegans was found to be expressed well in E. coli (designated cMCU).189
Using a combination of cryo-electron microscopy and 2D NMR spectroscopy, the structure
of cMCU was determined to be pentameric, with each subunit identical (Figures 2.4a and
2.4b).189 Each subunit consisted of a set of α-helices connected by a short disordered loop in
the intermembrane space and a disordered bulge about halfway through the trans-membrane
section (Figure 2.4b). The disordered loop had an amino acid sequence designated as the
DIME loop (Figure 2.4c). This loop was found to be well conserved across different homo-
logues of the protein – specifically the aspartic acid (D) and the glutamic acid (E) did not
change, while the isoleucine and methionine could vary.
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(a) (b) (c)
Figure 2.4: (a) Head-on structure of the cMCU from mitochondrial intermembrane space,
showing the transmembrane pore. Each color represents a subunit of the pentameric struc-
ture. (b) Side view of the cMCU, showing the transmembrane helices. (c) Schematic showing
the location of the conserved serine (S) and DIME loop. PDB 5id3.189
Adjacent to the DIME loop is a conserved serine residue. A point mutation of this serine to
alanine had no effect on protein function. However, the most common inhibitor for the MCU,
Ru360, was found to be less effective in this mutant.169 In contrast, mutation of aspartic
acid attenuated protein function significantly.185,189 Comparison with the human homolog
of the MCU by key amino acid mutations showed that the structure and function was the
same as in the cMCU.189 With the structure of the MCU solved several molecular docking
studies have been performed to analyze the molecular interactions of inhibitors.185,186
2.1.4 Ischemia reperfusion injury
In a heart attack, or myocardial infarction (MI) episode, a myocardial infarct (artery
blockage) forms constricting blood flow and reducing oxygen levels in tissue. As blood flow
is restricted, oxygen levels diminish and the heart enters a state of hypoxia. This process
stimulates anaerobic metabolism, producing high levels of lactic acid and lowering the cellular
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Figure 2.5: A schematic of ischemia and reperfusion. Under hypoxia, anaerobic respiration
is activated which lowers the pH via production of lactic acid and pumps calcium into the
cardiomyocte. The mitochondrial permeability transition pore (MPTP) remains closed and
myofibril contracture is inhibited. Upon return to the normoxic environment the lactic acid
buildup is flushed, restoring physiological pH. Calcium is pumped out of the myocytes by
the directional switching of the sodium calcium pump. ROS levels increase after restoration
of the electron transport change mechanism which will in turn stimulate the saroplasmic
reticulum to release more calcium, and inducing the opening of the MPTP. Additionally,
due to the restoration of the mitochondrial membrane potential, calcium will flood into the
mitochondria also leading to MPTP opening. This, as well as myofibril hypercontracture,
will result in tissue-level reperfusion injury. Schematic as suggested by Yellon et. al.190
pH (Figure 2.5, left).162,190 The mitochondrial permeability transition pore (MPTP, a channel
through the inner membrane within the mitochondria) will remain closed due to the low
pH. The excess H+ ions are removed by exchange with sodium ions via the sodium/proton
exchanger. The excess sodium ions in turn induce the sodium/calcium exchange protein to
remove sodium ions and bring excess calcium in. The acidic environment also inhibits the
electron transport chain, reducing the amount of ATP produced.
After the arterial blockage is cleared, the oxygen levels are restored (reperfusion) and
the lactic acid is flushed from the cell. The sodium-proton and the sodium-calcium pumps
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are stimulated, raising the intracellular sodium ion concentration and removing some of the
excess intracellular calcium (Figure 2.5, right). The restoration of neutral pH restores the
inner mitochondrial membrane potential, usually around -180 mV. Calcium will flood the
mitochondria upon this restoration. The electron transport chain reactivates and ATP syn-
thesis is restored. Reactive oxygen species (ROS) are a byproduct the electron transport
chain mechanism. As the ROS levels rapidly increase the sarcoplasmic reticulum releases
additional calcium. The sudden increase in mitochondrial calcium stimulates the opening
of the MPTP several minutes after reperfusion. The opening of the MPTP is key as it is
associated with the onset of apoptosis due to the decoupling (setting to 0 mV) of the inner
mitochondrial membrane potential and results in ATP depletion.191 The increase in cal-
cium levels will also induce myofibril contrature (contraction of the heart muscle), increasing
reperfusion injury. In vivo experiments inhibiting the sodium-calcium pumps, mitochon-
drial calcium uniporter, and sodium-proton pumps show decrease in infarct size; however
corresponding clinical studies are less promising.145,162,190,192–194
With short ischemic time periods reperfusion can be beneficial but if the ischemic times-
pan is excessive reperfusion injury occurs. Inhibition of reperfusion injury accounts for 50%
reduction of infarct size, suggesting that reperfusion is responsible for infarct formation. Sev-
eral different types of reperfusion injury have been shown to be possible; lethal reperfusion
injury is the method with the fewest therapeutic options and the most severe.162,195,196 The
other types of injury generally have therapeutic options or can be recovered from: reperfusion
arrhythmias, myocardial stunning, and the microvascular obstruction, discussed below.
Reperfusion arrhythmia (RA) was described over 30 years ago; it is the irregular rhythm
of the heart upon reperfusion.197 While this type of injury is undesirable on the long term,
the early evidence of RA can be considered therapeutically beneficial, particularly in STEMI,
the most severe form of myocardial infarctions. A number of therapeutics and treatment
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methods are well established for RA.198 Myocardial stunning, a second type of reperfusion
injury, is a form of mechanical dysfunction that persists in spite of blood flow restoration
and the apparent absence of irreversible damage.199–202 Although there are no established
therapeutic avenues, it is typically minor and does not greatly impact the quality of life.203 A
variety of hypotheses have been posited about the mechanism, however none have been con-
clusively confirmed.200,204–206 Another form of reperfusion injury is microvascular obstruction
(MVO): the “inability to reperfuse a previously ischemic region”.207 This is an irreversible
form of injury which will result in the death of the myocardial tissue. In patients with
STEMI, MVO is associated with larger infarct sizes and poorer short-term and long-term
prognoses.190,202,208–210 The fourth type is lethal myocardial reperfusion injury. This type is
characterized by the presence of viable myocytes at the end of ischemia, but subsequently die
during reperfusion.190,202 During this process contributions to myocyte death include (but
are not limited to) oxidative stress, calcium overload, and mitochondrial permability tran-
sition pore opening. There are limited therapeutic options currently, but lethal reperfusion
injury is considered a viable target.190
2.2 Inhibitors of the mitochondrial calcium uniporter
As mitochondrial calcium uptake is critically related to reperfusion injury, the inhibition
the MCU is a potential therapeutic target. A small number of inhibitors of the MCU have
been discovered, starting with ruthenium red (RuRed), and most recently, a few organic
inhibitors. The mechanism of action for effective inhibition is currently unknown, and new
inhibitor discoveries are infrequent. Two docking studies report that hydrogen bonding
to the amino acids at the opening of the MCU are critical. However, only one of these
reports systematically studied the structure-activity relationship of a number of potential
inhibitors.185,186
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2.2.1 Organic inhibitors
Several organic inhibitors of mitochondrial calcium uptake have been recently discov-
ered185,211–214. They are all relatively polar compounds containing number of hereoatoms
and a mix of aromatic and aliphatic regions (Fig. 2.6).
(a) (b) (c)
(d) (e) (f)
Figure 2.6: The organic inhibitors of the MCU investigated: (a) Necrox-5215, (b) KB-
R7943211, (c) DS16570511213, (d) minocycline216, (e) doxycycline216 and (f) mitoxantrone185.
The similarity of these structures suggests they operate by similar mechanisms of action.
However, each has been studied using different methods. Many experiments used whole cell
or tissue experiments, such as membrane polarization, ROS levels or Ca2+ levels within the
mitochondria to draw conclusions. A number of these experiments compared the potential
inhibitors to ruthenium red and Ru360, the commercially available and best studied MCU
inhibitors.
NecroX-5 is one of the members of the NecroX family of cell-permeable necrosis-inhibiting
drugs (Figure 2.6a).212,215,217 The NecroX family primarily localizes into the mitochondria,
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and is reported to have antioxidant activity. NecroX-5 was found to decrease mitochondrial
ROS generation and mitochondrial Ca2+ uptake, suggesting it inhibited the MCU. To deter-
mine the inhibitory activity, whole rats hearts or isolated myocytes were perfused first with
a hypoxic ischemic solution and then reperfused with normoxic solution with or without
NecroX-5 or ruthenium red. Infarct size, mitochondrial membrane potential, and mitochon-
drial calcium levels were determined. Treatment with ouabain, a Na+/K+ ATPase inhibitor
which induces mitochondrial Ca2+ overload, or histamine, a stimulant for calcium release
from the endoplasmic reticulum, with NecroX-5 suppressed the uptake of calcium into the
mitochondria. This suggests that NecroX-5 is a specific inhibitor of the MCU; no affect on
the Na+/Ca2+ ion channel was observed. No additional studies with NecroX-5 as an MCU
inhibitor have been published to date.
Another organic inhibitor of the MCU is KB-R7943 (Figure 2.6b).211 This compound
was initially discovered as a Na+/Ca2+ ion channel inhibitor, and was shown to also protect
against ischemia/reperfusion. Using the calcium dependent mitochondrial targeted photo-
luminescent protein aequorin, the levels of calcium within the mitochondria were analyzed
under various inhibitor concentrations. Via this method, the 50% inhibition constant of
calcium uptake (IC50) for KB-R7943 was found to be 5.5 µM in permeabilized HeLa cells.
Minocycline and doxycycline (Figures 2.6d and 2.6e) are two members of the tetracycline
family, a group of compounds used as antibiotics for many years.214,218,219 However, a few
of these compounds were found to have additional therapeutic value. One mode of action
was protection against reperfusion injury.216,220–222 When given to freshly isolated hepato-
cytes, both minocycline and doxycycline block mitochondrial calcium uptake and protect
against cell death induced by ischemia/reperfusion, with doxycycline being more effective.
These compounds also inhibited the mitochondrial permeability transition pore opening. In
comparison with Ru360, both of these compounds were less effective and appeared to be
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acting on the MCU. Full dose response curves were not determined, however from a 3-dose
study minocycline and doxycycline had 50% inhibition constants of about 20 µM and 5 µM,
respectively.
The aforementioned MCU inhibitors were all therapeutics initially utilized for specific
pathologies. Following this concept, recent work to discover additional inhibitors has focused
on high-throughput screenings of known small drug molecules. The first study discovered one
compound, DS16570511 (Figure 2.6c), out of a screen of 120,000 compounds using HEK293A
cells (healthy endothelial kidney cells).213 Although the assay was not discussed in detail,
the criteria for a positive result required an IC50 of 10 µM or below for the cell-based calcium
inhibition, a sevenfold lower IC50 for the isolated mitochondrial inhibition, a reproducible
inhibitory activity, and inhibition must be present in human cells, and both small and large
animals. The IC50 with isolated mitochondria was found to be 860 nM, compared with their
experimental value of 20 nM for Ru360. In permeabilized cells, the IC50 was significantly
larger: 7 µM.
The second example using high-throughput screening discovered mitoxantrone (Figure
2.6f) out of 70,000 compounds.185 The authors developed a high-throughput assay using iso-
lated yeast mitochondria expressing the mitochondrial-targeted aequorin luminescent protein
as a calcium probe. Since yeast do not express the MCU naturally, this method of screening
of potential MCU inhibitors is relatively straightforward. Additionally, the generation of
MCU mutants to probe the precise mechanism of inhibition is utilized. The authors ex-
pressed the D261A MCU mutant — the D261 conserved residue shown previously to be
necessary for inhibition. This aspartate residue is key for Ca2+ uptake; mutation to alanine
reduces protein function by about 4-fold. Inhibition of calcium uptake by ruthenium red
was also greatly attenuated, compared to the wild-type protein. However, mitoxantrone
inhibition was not significantly reduced by the D261A mutant, consistent with the MCU
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molecular docking studies. Significant hydrogen bonding occurred with the long side chains,
and the structure had a more flexible bonding mode due to binding via the ring and the
dual “arms” (Figure 2.6f). Modifications of those arms showed that the both chain length
and hydrogen bonding ability was critical for inhibition, Tests with the structural analog
containing CH2CH2NH2 arms (pixantrone) inhibited, but much more poorly. These studies
1) showed the difficulty in discovering new MCU inhibitors and 2) revealed clues into the
mechanism of action for effective inhibition.
2.2.2 Inorganic inhibitors
Ruthenium-based MCU inhibitors have been more extensively studied than the afore-
mentioned organic inhibitors. Additionally, some studies have considered other metal ions,
specifically La3+ and Co3+. To date, the most effective inhibitor is still ruthenium based223
and these types of complexes are the most commonly used.
Lanthanum and cobalt
La3+, along with ruthenium red (discussed below), was one of the first MCU inhibitors
discovered.224 At the initial discovery of the inhibitor action of RuRed and La3+, the pro-
teins responsible for calcium transport into the mitochondria were still unknown, although
the phenomenon of calcium transport was known and a subject a much research. Several
lanthanide ions were tested — lanthanum, europium, terbium, and neodymuium. La3+ was
found to inhibit calcium uptake, however over time the inhibitory ability decreased within
the sample, suggesting the La3+ ions were being taken up into the mitochondria. This de-
crease was attributed to the mitochondria actually uptaking the La3+, albeit slower than
Ca2+. The other lanthanide ions were found to behave in a similar manner. In addition,
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the inhibition leveled out without fully inhibiting calcium uptake. La3+ was found to bind
to additional sites on the mitochondria, termed “low affinity binding sites”. An additional
study found that lanthanum did not inhibit calcium movement, but seemed to localize the
in the mitochondrial membranes.225 Overall, these findings indicated that lanthanum was
not an effective inhibitor of calcium transport.
Two examples in the literature utilized cobalt complexes as MCU inhibitors. Four
cobalt candidates were considered: [(NH2(CH2)5NH2)Co(NH3)5]
3+, [Co(H2O)(NH3)5]
3+,
[Co(NH3)6
3+, and [Co(Ala)(NH3)5]
3+. Dose-response curves were determined, and the best
inhibitor was found to be [(NH2(CH2)5NH2)Co(NH3)5]
3+ with an IC50 of 140 nM on iso-
lated mitochondria from rat liver tissue.226 The second report investigated a number of
metal tris(ethylenediamine) complexes, including the metals Co(III), Rh(III), Cr(III), Ru(II),
Fe(III) and Cu(II).227 Of these, the Co(III) complex had the lowest IC50 at 53 nM, again
on isolated mitochondria. Co(III) hexaammine was tested with an IC50 at 550 nM. These
results indicate that relatively simple complexes are effective inhibitors, and was one of the
first examples showing that basic structural tuning may provide insight into the necessary
structure-activity relationship for MCU inhibition.
Ruthenium red and Ru360
Ruthenium red (RuRed) is a tri-ruthenium +6 cation that has been used for many years as
a histological stain (Figure 2.7a).228 Due to the high charge of RuRed, it binds very effectively
to mucopolysaccarides and has been reported to bind to nucleic acids. Additionally, it has
a very large extinction coefficient (68,000 M−1cm−1 at 532 nm) enabling easy microscopic
visualization.228–231
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(a) Ruthenium Red (RuRed) (b) Ru360
Figure 2.7: The chemical structures of the two common ruthenium based MCU inhibitors,
(a) ruthenium red (RuRed) and (b) Ru360.232,233
It had been observed that ruthenium red also stained mitochondria.234 Mucopolysac-
carides present on the mitochondrial membrane were known to be good calcium ion
binders.234,235 Thus, RuRed was considered as a candidate for altering the calcium bind-
ing of mitochondria.234 This study showed that 1) RuRed bound to rat liver mitochondria
on the same order of magnitude as Ca2+ binding and 2) RuRed inhibited Ca2+ uptake into
the mitochondria.234 The overall effect was complete inhibition of calcium-dependent respira-
tion, without effecting ADP phosporylation.224,236,237 At the time of these early studies, two
types of mitochondrial calcium binding sites were known, “high-affinity” and “low-affinity”,
although the proteins involved were not known. Both types of sites were inhibited by RuRed,
with the “high-affinity” sites more effectively inhibited.224 RuRed was determined to inhibit
calcium transport into the mitochondria, but had little effect on the eﬄux mechanism.238
Voltage-sensitive calcium channels, such as those found in neurotransmitters, were also in-
hibited by RuRed, although it was found to be cytotoxic, decreasing cell viability.237,239,240
These seminal studies established RuRed as an inhibitor of calcium transport into the mi-
tochondria, even though the exact mechanism of transport and the key proteins had yet to
be determined.
Although RuRed was used as a tool for many additional investigations, it was noticed
that the yield of preparation were low, typically 20% or less. It was suggested that a “color-
less contaminant” with a strong absorbance around 355 nm also had inhibitory properties, at
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a much higher activity per Ru atom than RuRed.241 An additional study showed that upon
repeated purification of RuRed, the activity actually decreased.242 These observations led to
the discovery of Ru360, a dinuclear oxo-bridged +3 cation, as a potent calcium ion inhibitor
(Figure 2.7b).233,243 In whole cardiomyocytes, both RuRed and Ru360 showed calcium up-
take inhibitory properties.119,244 As the different proteins involved in mitochondrial calcium
uptake were discovered and their mechanisms elucidated, both RuRed and Ru360 were ex-
tensively used.169,185,186,189,192,214,245–248 The most potent commercial inhibitors, Ru360 and
RuRed are often compared to other inhibitors.185,212,213,223,226,227 Mechanistically, few stud-
ies have been done. As mentioned above, early experiments established “high-affinity” and
“low-affinity” calcium binding sites, with the high-affinity sites more strongly inhibited than
the low-affinity sites. The high-affinity site could be the MCU whereas the low-affinity site
is likely the anionic phospholipid membranes. A molecular docking study of Ru360 into the
MCU pore showed a number of hydrogen bonding interactions with the conserved aspartate
of the DIME loop, similar to the docking study with mitoxantrone.185,186 Mutations of the
conserved aspartate (D261A) significantly decreased the calculated binding of Ru360. This
finding corroborated the experimental studies that showed the D261A mutant of the MCU
was significantly less sensitive to Ru360 inhibition.185,186,189
Of relevance for this discussion is the effect RuRed and Ru360 have on ischemic reper-
fusion injury (IRI). Since this is a calcium-dependent pathology, any potent inhibitor of
mitochondrial calcium may be therapeutically useful. The initial study using RuRed as
an IRI protective agent used adult rabbits, treating the hearts with 1 µM complex during
reperfusion. Afterwards, the rabbits were sacrificed and the hearts harvested for additional
studies. It was determined that the total tissue had an increase in calcium, however RuRed
was able to attenuate the levels of mitochondrial calcium.249 Additional studies found similar
affects in rat hearts; overall, RuRed had a larger effect on reperfusion injury with minimal
affect on ischemia.250,251 This is consistent with the expected mitochondrial calcium levels
35
in ischemic conditions vs. reperfusion conditions (Figure 2.5). Another study considered
the effect of RuRed as a protective agent on cold ischemia — or the ischemia generated
when a transplant organ is kept in cold storage.252 Calcium levels do increase under ischemic
conditions, and this is exacerbated when a tissue is chilled due to the disruption of ATP pro-
duction. In this case, there was an attenuation of cold ischemic conditions with treatment
of RuRed.
In the case of Ru360, a few studies also considered the protective effects. A common
compound that is frequently used to protect against IRI is cyclosporin A.190 Rather than
inhibiting calcium uptake into the mitochondria, cyclosporin A inhibits the opening of the
mitochondrial permeability transition pore.193,253–257 Already in clinical trials, cylcosporin A
is frequently used as the lead compound to compare potential IRI protective agents.258 In iso-
lated cardiomyocytes, Ru360 reduced the amplitude of pathological calcium ion oscillations
associated with reperfusion injury, with similar efficacy as cyclosporin A.255 Several studies
showed that Ru360 protected against IRI by limiting the level of mitochondrial calcium dur-
ing ischemia and reperfusion.259,260 Ru360 was also found to accumulate in cells in a biphasic
manner, the first, quicker binding, associated with cell membrane binding and the second,
slower accumulation, with intracellular uptake.119 An in vivo study was consistent with the
aforementioned in vitro findings. Only 2.1 pmol Ru360/mg protein from myocardial tissue
was detected - much lower than the IC50 of Ru360, thus implying that less than complete in-
hibition would occur. Ventricular tachycardia (VT) and ventricullar fibrillation (VF) are two
pathologies observed in reperfused hearts. In spite of the low levels of Ru360 accumulation,
in treated hearts VT and VF were both completely absent. In addition, Ru360 significantly
protected against reperfusion induced oxidative damage.261 These studies indicate the great
therapeutic potential of ruthenium-based MCU inhibitors. One limitation has been lack of
effective cellular uptake; another has been characterization of off-target inhibition. Although
Ru360 has been touted as a highly selective inhibitor, no studies have attempted to consider
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other protein targets. This opens up the possibility of many research avenues, including
molecular tuning and structure-activity relationships, as well as extensive molecular biology
investigations. We have explored a few examples of structure-activity relationships and the
effects of small molecular changes on the biological activity.
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CHAPTER 3
SYNTHESIS AND CHARACTERIZATION OF A RU360 ANALOG
3.1 Introduction1.
The trinuclear oxo-bridged ruthenium complex, ruthenium red (RuRed, Figure 3.1a) is
a commercially available inhibitor of the mitochondrial calcium uniporter (see Chapter 2 for
more detail). The use of RuRed, however, is limited by its poor selectivity for the MCU, as
well as by the large number of impurities found in commercial sources of this compound.224,242
The history of this complex is of interest due to its relationship to Ru360, the most commonly
used inhibitor today. RuRed was initially discovered in the late 1800s and has since been
used as a cellular stain due to its intense magenta-red color and high positive charge.228,231,262
RuRed can be prepared by treating RuCl3 with concentrated aqueous ammonia.
230,263 A
single report used [Ru(NH3)5Cl]Cl2 in the presence of aqueous ammonia and 10% oxygen
to produce a compound reported as RuRed. However, the only reported characterization
was a resonance Raman spectrum consistent with RuRed.264 The reaction starting with
RuCl3 did not produce pure product: Fletcher et al. reported an impurity visible by UV-vis
spectroscopy at 725 nm.230 Luft purified RuRed by recrystallization and isolated the 725 nm
fraction, dubbing it “ruthenium violet”.228,230 The reaction to synthesize RuRed was quite
low yielding (20% or less) suggesting that other compounds were present. A contaminant
with a strong absorbance around 355 nm contained high levels of ruthenium, leading to the
discovery of Ru360, a dinuclear ruthenium oxo-bridged complex.233,241,243
The structure of the RuRed was not solved for almost 100 years after the initial synthetic
report.230,232,262,263,265 The first attempt solved the X-ray crystal structure as a “chloroxy”
1Chapter reproduced in part with permission from Inorg. Chem., 2017, 56(6), pp 3123 - 3126. Copyright
2017, American Chemical Society
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complex without a clear bridging system between the metal centers.266 This structure was
proven incorrect by the formation and subsequent X-ray structure determination of the thio-
sulfate salt, suggesting the initial structure reported was of an impurity.232 Substitution
of the four ammines for two ethylenediamine ligands on the center ruthenium of RuRed
produced a complex that contained two µ-oxo moieties (Figure 3.1a)267. This simple substi-
tution corroborated the existence of three ruthenium atoms and two µ-oxos as the backbone
of RuRed. Spectroscopically, comparison with a previously discovered µ-oxo bridged ruthe-
nium system, K4[Ru2OCl10], assisted in determining the RuRed structure. The Ru-O-Ru
vibration is characteristic in the infrared spectrum; K4[Ru2OCl10] RuRed have a Ru-O-Ru
stretches at 888 cm−1 and 813 cm−1, respectively.268,269
Charge balance necessitates that the ruthenium atoms exist in different oxidation states,
the outer two in the +3 state and center atom in the +4 state. Upon a 1-electron oxidation
the oxidation states of the outer ruthenium atoms each increase to a formal +4 while the
inner decreases to +3; this oxidized product is called “ruthenium brown”.230 Ruthenium-
99 Mo¨ssbauer spectroscopy was used to probe the valence delocalization of the ruthenium
centers.270,271 Although the acquired Mo¨ssbauer results for RuRed were consistent with a
RuIII-RuIV-RuIIIbackbone, this hypothesis was not compatible upon oxidation to ruthenium
brown. The expected spectral features for ruthenium brown were similar to RuRed: the
same isomer shifts but a 2:1 RuIV:RuIII pattern for ruthenium brown. However, the isomer
shifts were larger than expected and the RuIV:RuIII patterns were not what was expected.
Wagner and co-workers attribute this discrepancy to the 1-electron oxidation not coming
from a distinct center, but “smeared” over the entire backbone.271 Thus the interpretation
is that RuRed and ruthenium brown are valence-delocalized across the µ-oxo backbone and
the ruthenium metal centers do not have discrete oxidation states.
Commercially available RuRed preparations are still notoriously impure, which inhibits
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its use as a precise therapeutic (see Chapter 2 for therapeutic applications of RuRed).242
One of the impurities found in formulations of RuRed is a dinuclear oxo-bridged compound,
[(HCO2)(NH3)4Ru(µ–O)Ru(NH3)4(O2CH)]
3+ (Figure 3.1b).233,243 This compound was se-
lectively synthesized from RuCl3 and aqueous ammonia. Purification of Ru360 was accom-
plished with cellulose-based, weakly acidic cation exchange chromatography using What-
man CM-52 resin and ammonium formate (NH4HCO2) buffer as the mobile phase. This
gave Ru360 as the formate-capped form, [(HCO2)(NH3)4Ru(µ–O)Ru(NH3)4(O2CH)]
3+ in
low yield.
(a) Ruthenium Red (RuRed) (b) Ru360
Figure 3.1: The chemical structures of the two common ruthenium-based MCU inhibitors,
(a) ruthenium red (RuRed) and (b) Ru360.232,233
Through our investigations of Ru360, we synthesized and characterized a functional ana-
logue. This analogue, [(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
5+ (3.1), is a simple variation
of Ru360 where the axial formate ligands are replaced by water molecules. Three distinct
synthetic methods for its isolation and detailed physical characterization are reported. Addi-
tionally, the potent inhibition of mitochondrial calcium uptake in both permeabilized human
cells and isolated yeast mitochondria expressing the human MCU and its essential regulator
EMRE is demonstrated in Chapter 5.
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3.2 Synthesis and purification2
In our initial efforts we followed the previously reported synthesis for Ru360.233,243 Briefly,
RuCl3 · n H2O was treated with 6 M HCl containing 12% ethanol and heated at 90 °C to
reduce any Ru(IV) and nitrosyl impurities (Figure 3.2). Concentrated NH4OH was added
to precipitate a solid material, which was then re-suspended in additional concentrated
NH4OH and heated at 40 °C overnight. Notably, this step of the reaction required a sealed
reaction vessel; heating in an open container did not produce the desired compound (3.1).
The reaction mixture was centrifuged to isolate the final crude solid. The desired product
was readily identified by a UV-vis absorbance band centered at 360 nm. The formation
of RuRed as a byproduct was also evident in the crude mixture from a broad absorbance
band centered at 530 nm. Due to the unavailability of the Whatman CM-52 resin, the
resin used in the published preparation, we investigated alternative solid-phase supports
for purification. A column packed with the strongly acidic cation exchange resin, Dowexr
50WX2, and a mobile phase of HCl was found to be effective for purification, as these were
previously used for isolating a chloride-capped analogue of Ru360. The column was prepared
and packed with 0.1 M HCl and eluted starting at 1 M HCl. At 2 M HCl, a byproduct of
this reaction, confirmed to be [Ru(NH3)5Cl]Cl2 by single-crystal X-ray diffraction (Figure
3.3a and Table 3.1), eluted as a yellow band. Upon increasing the HCl concentration to
2.5 M and then 3 M, pure compound 3.1 came off the column as a green-brown solution.
At higher HCl concentrations (>4 M), RuRed and its oxidized form, ruthenium brown,
could also be eluted, as evidenced by the red-brown color in the fractions. Fractions were
tested by UV-vis for purity, checking for the diagnostic 360 nm band. These fractions
were evaporated to afford a green-brown solid, which elemental analysis formulates to be
[(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]Cl5·1.5 H2O, in typical yields of 10 to 20 mg (1.7 to
3.4%) starting from 250 mg of RuCl3 · n H2O. The low yields can likely be accounted for due
2Additional details for all syntheses can be found in appendix A.
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the limited solubility of the crude compound in acid when it was loaded on the column. The
low yields and tedious purification prompted us to search for alternative synthetic methods
for preparing compound 3.1.
Figure 3.2: The three methods used to synthesize the Ru360 analog
[(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
5+
(3.1).
[Ru(NH3)5Cl]Cl2 was synthesized following previously reported procedures and charac-
terized by IR spectroscopy (Table 3.4). We found that heating [Ru(NH3)5Cl]Cl2 in 1 M
NH3 in a capped reaction vessel at 75 °C for 6 h followed by stirring at room temperature
for 3 days gave rise to a dark green solution with an intense absorbance band at 360 nm,
an indicator of a Ru360-like complex (see Figure 3.2, Method 2). When the reaction vessel
was capped, no formation of RuRed is observed. Performing the same purification by ion-
exchange chromatography with Dowexr 50WX2 resin, as described above, afforded 3.1, also
as a green-brown solid. The typical yields for this method were on the range of 10 to 20%
starting from [Ru(NH3)5Cl]Cl2. While the yield was significantly increased for this method,
it was still quite low. As some starting material was isolated during the purification, it is
likely the reaction does not go 100% to completion. Increasing the reaction time, or tuning
the conditions further may alleviate the problem.
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We also explored the utility of [Ru2OCl10]
4− as a synthon for these complexes containing
the Ru(µ-O)Ru core. The compound K4[Ru2OCl10] was prepared as described previously
and characterized by single-crystal and powder X-ray diffraction (Figures 3.3b and A.1 and
Table 3.1). Accordingly, the reaction of [Ru2OCl10]
4− with concentrated NH4OH at 50
°C for 30 min produced [(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]5+ as the major product de-
tected by UV-vis spectroscopy (Figure 3.2, Method 3). After purification by cation exchange
chromatography, the complex was isolated in typical yields of 4 to 8%. Longer or higher
temperature reaction conditions were found to favor an unknown purple colored side product
and significantly reduced the yield. Shorter and lower temperature conditions were found to
inhibit the reaction substantially. The product obtained from each of the three methods was
fully characterized by UV-visible, infrared, and electron paramagnetic spectroscopies, cyclic
voltammetry, and X-ray crystallography.
3.3 Characterization results and discussion
3.3.1 X-ray crystallography3
Diffraction quality crystals of [Ru(NH3)5Cl]Cl2 were grown from slow evaporation of
2 M HCl solutions obtained from the cation exchange chromatography. [Ru(NH3)5Cl]Cl2
crystallized into yellow blocks in the orthorhombic space group Pnma (Table 3.1). The
dichloride salt X-ray structure has only been recently published by this author; the analogous
copper oxalate salt was published in 2014 by Martynova and co-workers.223,272 The Ru–N
and Ru–Cl bond distances are comparable for both compounds, as expected, although the
space groups were not the same. A crystallographic mirror plane bisects the N3-Ru-Cl plane;
positional disorder is apparent in the hydrogens on N1, N2, and N3 (Figure 3.3a).
3Thanks to Samantha N. MacMillan for all crystal structure data collection and refinement.
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(a) (b)
Figure 3.3: The X-ray crystallographic structures of (a) [Ru(NH3)5Cl]Cl2 and (b)
[Ru2OCl10]
4− grown from slow evaporation of 2 M and 2.5 M HCl solutions at room temper-
ature and elevated temperature, respectively. Thermal ellipsoids are at the 50% probability
level. Reproduced with permission from Inorg. Chem., 2017, 56(6), pp 3123 - 3126. Copy-
right 2017, American Chemical Society.
The synthesis and X-ray structure of [Ru2OCl10]
4− has been reported previously.268 Due
to limited methods for characterization we obtained the X-ray crystal structure and powder
X-ray diffraction to verify identity and purity (Figure 3.3b and A.1). Slow evaporation at
50 °C of a 2.5 M HCl solution of [Ru2OCl10]4− produced red blocks of good quality in the
highly symmetric tetragonal space group I4/mmm. The space group and bond lengths and
angles matched those of the previously reported crystal structure.268 The Ru-O-Ru bond
is bisected by two perpendicular mirror planes and a third mirror plane sits through the
oxygen, generating the exactly 180° Ru-O-Ru bond. The simulated powder diffraction was
calculated using Mercury based on the crystal structure and compared to the experimental
data — good agreement indicated that the bulk sample was pure (Figure A.1).
Crystals grown from solutions of 3.1 exhibited two different polymorphic forms. The
vapor diffusion of ethanol into aqueous solutions yielded dark red prisms (see Figure 3.4a),
whereas the slow evaporation of 3 M HCl solutions gave rise to green dichroic needles (see
Figure 3.4b). Analysis of the red prisms revealed an oxo-bridged dinuclear Ru structure of
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(a) (b)
Figure 3.4: (a) The red polymorph grown from ethanol diffusion into aqueous solutions of
3.1. (b) Green polymorph obtained from slow evaporation of 3 M HCl solutions of 3.1
the formula [(OH)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
4+ (Figure 3.5, Table 3.14). This formula
differs from that of [(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
5+ by the loss of one equivalent
of HCl to give a mixed aqua-hydroxo compound. The bridging µ-oxo-ligand sits on a crys-
tallographic inversion center. Thus, the ammine ligands assume an eclipsed conformation,
and the Ru-O-Ru angle is exactly 180°.
Figure 3.5: The solid state structure of [(OH)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
4+, grown
from ethanol diffusion into aqueous solutions. Thermal ellipsoids are at the 50% probabil-
ity level. Reproduced with permission from Inorg. Chem., 2017, 56(6), pp 3123 - 3126.
Copyright 2017, American Chemical Society.
4Relevant bond distances and angles in Appendix A.
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Such geometric features are also present in the formate-capped Ru360 ion, which lies on
both a crystallographic inversion center and mirror plane119,233. Based on hydrogen-bonding
patterns in the lattice (vide infra), we assign the axial ligands as water and hydroxide.
However, only one hydrogen atom could be conclusively identified in the difference Fourier
map. Inspection of intermolecular interactions between axial oxygen ligands on neighboring
cations reveals the presence of a close contact of 2.446 A˚ (Figure 3.6). These two oxygen
atoms are related by a crystallographic inversion center; in addition, the distance between
atoms is too short to constitute a normal hydrogen bonding interaction. We hypothesize
that this situation represents a symmetric hydrogen bond where the hydrogen atom is shared
equally between both donor oxygen atoms.
Figure 3.6: Intermolecular symmetric hydrogen bond interaction between axial ligands of
[(OH)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
4+. Thermal ellipsoids are at the 50% probability
level. Reproduced with permission from Inorg. Chem., 2017, 56(6), pp 3123 - 3126. Copy-
right 2017, American Chemical Society
This hydrogen atom, which could not be located in the difference Fourier map, is inferred
to lie on the crystallographic inversion center at the midpoint of the symmetric hydrogen
bond. Accounting for this shared hydrogen atom, the net formula for the complex cation
in the solid state is [(OH)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
4+. Four outer-sphere chloride
ions are also present (not shown in figures). The net balance of the charge, accounting for
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the hydrogen atom on the inversion center, results in the expected mixed-valent RuIII/RuIV
oxidation state, which is well characterized for Ru360.233
Table 3.1: X-ray Crystallographic Data Collection and Refinement Parameters for
[Ru(NH3)5Cl]Cl2, K4[Ru2OCl10] and [(OH)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]Cl4
Crystal Data [Ru(NH3)5Cl]Cl2 K4[Ru2OCl10] [(HO)(NH3)4Ru(µ
–O)Ru(NH3)4(OH2)]Cl4
Formula Weight 292.59 729.04 530.23
Temperature/K 223 223 223
Crystal System Orthorhombic Tetragonal Monoclinic
Space Group Pnma I4/mmm P21/n
a/A˚ 13.3791(12) 7.0951(13) 8.2808(5)
b/A˚ 10.5086(8) 7.0951(13) 11.7183(7)
c/A˚ 6.7456(6) 17.034(4) 9.0833(5)
α/° 90 90 90
β/° 90 90 96.612(3)
γ/° 90 90 90
Volume (A˚3) 948.40(14) 857.5(4) 875.55(9)
Z 4 2 2
D, g cm−1 2.049 2.824 2.011
µ (mm−1) 2.438 4.266 2.334
Observed reflections 1288 462 2171
Parameters 53 20 86
R1 (I >2σ)a 0.0241(1166) 0.0228(408) 0.0265(1995)
wR2 (I>2σ)b 0.0608(1288) 0.0547(462) 0.0655(2171)
GOFc 1.099 1.124 1.091
aR1 = Σ||Fo|-|Fc||/Σ|Fo|. bwR2 = {Σ[w(F 2o − F 2c )2]/Σ[w(F 2o )2]}1/2.
cGOF = {Σ[w(F 2o − F 2c )2]/(n− p)}1/2.
The green needle polymorph (Figure 3.4b, Table 3.2) of this compound gave data that
appeared suitable for X-ray diffraction. Although initial structure solution was successful,
full refinement of the structure was hindered by unresolved twinning issues.
47
Table 3.2: Unit Cell Parameters and Tentative Space Group Assignment for the Green
Polymorph
Crystal Data
Morphology Needle
Crystal System Monoclinic
Space Group P21/c
Volume/ A˚3 3464
a/A˚ 14.51
b/A˚ 9.23
c/A˚ 26.40
α/° 90
β/° 101.72
γ° 90
Basic atomic connectivity obtained from this data, however, revealed a structure largely
similar to that of the red polymorph. Namely, a linear Ru-O-Ru complex with axial ligands
believed to be oxygen-atom donors based on the electron density contributions of the dif-
ference map and the interatomic distances. This structure suggests that even in 3 M HCl,
chloride ions do not bind directly to the axial sites.
3.3.2 UV-visible and infrared spectroscopy
Compound 3.1 was further characterized by UV-visible (UV-vis) and infrared (IR) spec-
troscopy. The UV-vis absorption spectrum revealed a diagnostic absorbance band centered
at 360 nm, a feature which gives Ru360 its name (Figure 3.7 and Table 3.3). A lower energy
transition centered at 600 nm gives rise to the observed green color of these compounds in
solution. The intensity of this transition varied slightly depending on the synthetic method
used to prepare the complex. The variance between the different preparations is tentatively
attributed to the presence of small quantities of the RuRed ion, which has a large molar
absorptivity (68,000 M−1 cm−1) at 530 nm. The UV-vis spectrum is pH dependent, presum-
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Table 3.3: Extinction coefficients for the three synthetic methods taken in pH 7.4 phosphate-
buffered saline (PBS)
Absorption wavelength Method 1 Method 2 Method 3
360 nm [M−1cm−1] 27000 ± 6000 26000 ± 3000 28000 ± 4000
600 nm [M−1cm−1] 430 ± 310 850 ± 90 780 ± 100
1180 nm [M−1cm−1] 180 ± 10 99 ± 14 125 ± 14
ably due to the degree of protonation of the axial aquo ligands. For the previously prepared
aqua- and hydroxo-capped analogues, the absorbance maxima are at 335 and 593 nm at
pH 2, and 360 and 612 nm at pH 9, respectively.233 We found at pH 7.4 the axial ligands
are most like fully protonated (aqua-capped), based on the similarity between the acquired
spectra and the previously reported spectra.233
Figure 3.7: The UV-vis spectrum of all three preparations methods for compound 3.1.
Reproduced with permission from Inorg. Chem., 2017, 56(6), pp 3123 - 3126. Copyright
2017, American Chemical Society.
Consideration of the molecular orbital diagram and DFT analysis clarifies the mixed-
valence character of the system and the transitions observed in the UV-vis spectrum.
The molecular orbital (MO) diagram for dinuclear ruthenium µ-oxo bridged species was
originally developed using K4[Ru2OCl10], and further adapted to study the blue dimer,
([Ru2O(bpy)4](PF6)2), [Ru2O(NH3)10]
4+/5+, as well as other mixed-valent compounds.273–277
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Following the example laid down by Orgel and co-workers, the ruthenium centers each can
be considered C4v symmetry and will transform as 3a1+a1+a2+2a.
273 The ammines and
aquo ligands are sigma donors, and therefore will transform as 2a1+a1+a and the µ-oxo
σ-bond will transform as A1. This leaves a2 and a as the orbitals to form the pi-bonds.
Considering the entire molecule (C4v × i = D4h), this leads to an energy level ordering of
(ebu)(b2g)(b2u(eg)(e
a
u) (Figure 3.8a). The total number of electrons is 13: 9 from the two
ruthenium atoms and 4 from the x and y orbitals of the oxygen. Filling up the MO diagram
leaves one electron unpaired in the eau orbital. The molecular orbital generation, and the
energy level ordering is corroborated by DFT calculations (Figure 3.8a).
(a) (b)
Figure 3.8: (a) The MO diagram (pi system only) with symmetry assignments and DFT
calculated density orbitals. Energy levels from DFT calculations. (b) The calculated UV-
vis transitions by TDDFT analysis compared with the experimental. Electronic transitions
illustrated as going from dark red to light green.
Thus, a III/IV system will be paramagnetic, a III/III system will be paramagnetic and a
IV/IV system will be diamagnetic (Figure 3.8a). TDDFT analysis of 3.1 revealed the 360
nm band to be a LMCT with charge density going from the ammine and aquo ligands to the
ruthenium metal centers. The 600 nm band is the HOMO pi* (eau) to σ* electronic transition
(Figure 3.8b).
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In the infrared spectrum, the ammine N–H vibrational modes dominate, visible at 3200,
1618, and 1313 cm−1 (Figure 3.9a and Table 3.4).
(a) (b)
Figure 3.9: The IR (a) of all three preparations methods for compound 3.1. The IR spectra
from deuterated 3.1 (b) showing the Ru-O-Ru vibrational mode (black arrow). Reproduced
with permission from Inorg. Chem., 2017, 56(6), pp 3123 - 3126. Copyright 2017, American
Chemical Society.
The Ru-O-Ru stretching mode resonates at 850 cm−1; this mode was identified by deuterium
isotopic labeling of the NH3 ligands to shift these vibrational frequencies to lower energies
(Figure 3.9b). The isotopic labeling was accomplished by dissolving compound 3.1 in D2O
to exchange the ammine and aquo protons for deuterium and then lyophilizing the solvent.
The Ru-O-Ru value (850 cm−1) differs only slightly from that for K4[Ru2OCl10], which is
reported at 888 cm−1.278–280
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Table 3.4: Infrared spectroscopy vibrational frequencies for [Ru(NH3)5Cl]Cl2 and compound
3.1, in proton form and deuteron form. Qualitative assignments: s = strong, m = medium,
w = weak, sh = shoulder, bd = broad.
[Ru(NH3)5Cl]Cl2 [Ru2O(NH3)8(H2O)2]Cl5 [Ru2O(ND3)8(D2O)2]Cl5
3213 (m) 3500 (sh)
1608 (m) 3234 (m)
1298 (s) 3149 (m) 3016 (m, bd)
798 (s) 2432 (s)
2293 (m)
1618 (w) 1625 (w)
1313 (s) 1409 (w)
1176 (w)
1068 (w)
1012 (s)
927 (w)
815 (s, bd) 850 (m)
626 (m)
The [(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
5+ symmetric and asymmetric N-H stretches
(3300 to 3100 cm−1) shift to lower frequencies as expected (2450 to 2300 cm−1).264,269,276 The
shoulder at ∼3500 cm−1 shifts to 3016 cm−1 and can be assigned as the coordinated H2O.
The bending vibration occurs at 1313 cm−1 and shifts to 1012 cm−1. The small vibrational
modes between 1200 and 900 cm−1 are most likely due to incomplete deuteration. The
vibration at 1618 cm−1 shifts to 1409 cm−1 and can be assigned as another N-H bending
mode.
3.3.3 Cyclic voltammetry, electron paramagnetic resonance and
near-infrared spectroscopy
To further explore the mixed-valent character of this complex we employed cyclic
voltammetry (CV), electron paramagnetic resonance (EPR), and near-infrared (NIR) spec-
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troscopies. Cyclic voltammetry of [(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
5+ in 0.10 M,
pH 7.6 NH4HCO2 buffer afforded two electrochemical processes (Figure 3.10a). Two se-
quential quasi-reversible reductions, representing transitions to the [IV,IV]/[III,IV] and
[III,IV]/[III,III] couples, are present at E1/2 = +0.12 V and E1/2 = –0.42 V, respectively.
The assignments are based on the resting potential of the complex, assigned as the mixed
valent [III/IV]. The [IV,IV]/[III,IV] and [III,IV]/[III,III] potentials fall between those mea-
sured previously for the aqua- and hydroxo-capped analogues, which were measured at pHs
of 2 and 8.15233. The comproportionation constant, Kc, which reflects the stability of the
mixed-valent state, is calculated to be 3.0 × 1010 for the [III,IV] state based on the 620 mV
separation between the [IV,IV]/[III,IV] and [III,IV]/[III,III] couples.281
(a) (b)
Figure 3.10: The (a) CV of all three preparation methods for compound 3.1 in pH 7.6, 0.10
M NH4HCO2 buffer. (b) EPR spectra of all three preparations for compound 3.1 at 77
K. The arrow indicates an intensity dip due to paramagnetic impurities in the instrumental
cavity. Reproduced in part with permission from Inorg. Chem., 2017, 56(6), pp 3123 - 3126.
Copyright 2017, American Chemical Society.
X-band EPR spectroscopy of [(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
5+ (Figure 3.10b)
at 77 K reveals a broad signal at g = 1.69, consistent with a paramagnetic RuIII/RuIV
mixed-valent ground state. Although the RuIII/RuIII is also paramagnetic, previous work
on the RuIII/RuIII blue dimer revealed that this oxidation state is EPR silent. A Loretnzian
53
fit of the signal gives a width of 136 G; the classic EPR derivative lineshape was not ob-
served. The broad line shape was likely due to a shorter than normal relaxation times.282
The width of the signal is consistent with other reported diruthenium bridged systems.
The Creutz-Taube ion contains a bridging pyrazine and has a temperature dependent
linewidth ranging from 120 G at 2 K to 350 G at 200 K.283 Mixed-valent oxo-bridged
RuIII/RuIV complexes bearing polypyridyl ligands display broad signals ranging from g =
1.39 to 1.79 (no line widths reported), which are also consistent with our observation for
[(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
5+.284–286 Oddly, the EPR signal of Ru360 reported
by Emerson and co-workers was reported to be an absorption at g = 2.06.283 RuCl3 has an
EPR signal at g = 2.09, potentially indicating a contamination in the reported spectra.
A NIR transition, centered at 1180 nm (8480 cm−1), arises from the intervalence charge
transfer (IVCT) associated with this mixed-valent complex.287 The high comporportionation
constant determined from the CV, would suggest a Class III, fully delocalized, system based
on the Robin and Day classifications, however more precise analysis can be done.231 The
reorganization energy, λ can be calculate using the full-width half-max of the transition.
(Equation 3.1).287,288 This is a term describing the free energy difference between DBA and
ABD, where DBA is the donor state and ABD is the acceptor state.287
∆ν1/2 = [2310λ]
1/2 (3.1)
The degree of delocalization can be established by calculating Hab for the transition. Hab is
a parameter describing the electronic interaction between the donor and acceptor states. It
can be calculated using the extinction coefficient of the transition (), the distance between
the donor and acceptor atom (rab), the transition maximum and full-width half-max:
H2ab =
maxνmax∆ν1/2
2.36× 103r2ab
. (3.2)
Comparison between λ and Hab gives an easy way to establish the class of the IVCT transi-
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tion. Using
Γ = 1/2− (λ− 2Hab)/∆ν1/2,
between 0 < Γ < 0.1 is Class I, 0.1 < Γ < 0.5 is Class II, and Γ > 0.5 is Class III (Table
3.5).
Table 3.5: Near-IR calculations to determine the extent of delocalization for compound 3.1,
all three synthetic methods.
FWHM [cm−1] λ [cm−1] Hab [cm−1] Γ [cm−1]
Method 1 1069 494 229 0.47
Method 2 1165 587 177 0.30
Method 3 1146 568 197 0.35
Based on this analysis the compound has a Class II assignment; this is also corroborated
by the low extinction coefficients of the complex.
Figure 3.11: The near-IR spectra of all three preparation methods.
3.3.4 Aqueous stability
The biological activity of compound 3.1 will be discussed in Chapter 5. However, previous
reports suggest lack of aqueous stability for Ru360 and RuRed233,243,263. To ensure aqueous
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stability under the working conditions of our aqueous stock solution, the freeze-thaw stability
and long-term stability was analyzed by UV-vis spectroscopy.
(a) (b)
Figure 3.12: The freeze-thaw stability (a) over several cycles and the long term frozen
stability (b) of the Ru360 analog. Reproduced with permission from Inorg. Chem., 2017,
56(6), pp 3123 - 3126. Copyright 2017, American Chemical Society
The spectra did not significantly change after five freeze-thaw cycles over five days, with
a freezer temperature of -20 °C and stock solutions prepared in MilliQ 18 MΩ·cm water.
Additionally, a stock solution that was kept at -80 °C for three months was determined to
be greater than 90% pure.
In addition, the stability in the biologically relevant reducing agent, glutathione, and the
stability in cell growth media (DMEM with 10% FBS) was probed by EPR spectroscopy.
Compound 3.1 was incubated at 37 °C for 24 hours in either 5 mol equivalents of glutathione,
or in cell growth media for 24 hours. The change in the presence of glutathione was significant
(Figure 3.13a). Compound 3.1 (evident as the broad signal at ∼4000 G, t = 0) was no longer
observed after 24 hours. The reaction also proceeded quickly, as the peaks at 2500 Gauss
at t = 0 began to form in the time needed to prepare the sample. The absorptions below
3500 Gauss are consistent with RuIII EPR signals.289–291 Similarly, in cell growth media an
absorption grows in at ∼ 2500 Gauss, most likely a RuIII species (Figure 3.13b). These
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two studies indicate that compound 3.1 was not significantly stable in biologically relevant
solutions.
(a) (b)
Figure 3.13: (a) The stability of compound 3.1 in 5 mol equivalents glutathione after 24 h
incubation. (b) The stability of compound 3.1 in DMEM containing 10% fetal bovine serum
after 24 h incubation.
3.4 Conclusion
In summary, the synthesis and characterization of a structural and functional analogue
of Ru360 is described. This compound was prepared via three different synthetic routes and
characterized by UV-vis spectroscopy, IR spectroscopy and X-ray crystallography. The two
newly developed synthetic methods may be more broadly applicable for the preparation of
new complexes with the Ru-O-Ru core, facilitating the discovery of new potent inhibitors
of the MCU based on ruthenium. This system is consistent with a delocalized mixed-valent
species, based on EPR spectroscopy, cyclic voltammetry and near-IR spectroscopy. Analysis
of the near-IR data establishes the compound as a Class II complex. DFT calculations
revealed additional insight into the molecular orbital diagram and the nature of the UV-
vis transitions. This species was found to be stable under long-term cold storage, but was
unstable in biologically relevant solutions. Future directions for this compound include
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exploring axial ligand substitutions as well as different equatorial ligands to build a library
of complexes.
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CHAPTER 4
SYNTHESIS AND CHARACTERIZATION OF µ-NITRIDO RUTHENIUM
COMPLEXES
4.1 Introduction
The best-characterized inhibitor of the MCU is the dinuclear oxo-bridged ruthenium
complex Ru360, [(HCO2)(NH3)4Ru(µ-O)Ru(NH3)4(O2CH)]
3+.119,233,243 The mechanism by
which this compound inhibits the MCU, however, is not well understood, and therefore the
structural features that give rise to its MCU-inhibitory properties are still under investiga-
tion. Studies of MCU inhibitors frequently use of Ruthenium Red (RuRed) or Ru360 as
discussed in Chapters 2 and 5. We showed that substitution of the axial formate groups on
Ru360 with axial waters greatly enhanced the inhibitory efficacy (see Chapter 3).223 This
finding suggests that the ligand environment around the Ru-O-Ru core has a significant effect
on the compound’s activity. Additionally, a relatively unique structural feature of Ru360
that may contribute to its biological activity is its linear Ru-O-Ru core. A similar albeit less
common motif is the linear bridging nitrido core, Ru-N-Ru, which is observed in a smaller
subset of compounds.292–305 However, the biological activity for this class of compounds has
not been explored. Due to the structural similarity to Ru360, and therefore the possibility of
biological activity, we set out to synthesize and characterize dinuclear ruthenium complexes
with the bridging nitrido motif.
Two major synthetic methods have been used to access µ-nitrido diruthenium complexes.
The first involves the well characterized compound, K3[Ru2NCl8(H2O)2] (4.SM2) as a gen-
eral synthon, which is can be transformed via direct ligand substitution of the chlorides.293–295
Previously explored ligands using this method include dithiocarbamates, bipyridines, and
ammines. The second method utilized ruthenium azide complexes with the ligands already
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installed and are decomposed to release N2, forming the µ-nitrido complex. This method was
applicable for the synthesis of a variety of ligand substitutions, including o-benzoquinone,
porphyrin and mercapto-phenylthio complexes.300–305 The ammine, ethylenediamine (en),
and 2,2’-bipyridine (bpy) substitutions were synthesized in the initial reports of Ru-N-Ru
complexes293,294; however, they were only characterized using infrared spectroscopy and el-
emental analysis. A later report provided the X-ray crystal structure of the en substituted
complex, which revealed a bridging en group between the two ruthenium atoms.295
Herein we report the syntheses of the ammine (4.1), en (4.2), bpy (4.3), 4,4’-
dimethyl-2,2’-bipyridine (4.4) and 4,4’-dimethoxy-2,2’-bipyridine (4.5) complexes starting
from 4.SM2 with full characterization by UV-vis, infrared, nuclear magnetic resonance
spectroscopies, and small-molecule X-ray crystallography. 4.1 and 4.2 were also character-
ized by conductivity1; this could not be performed on compounds 4.3, 4.4 and 4.5 due to
lack of aqueous solubility. The kinetics of aquation for compounds 4.1 and 4.2 are also
reported. The corresponding biological activity of these complexes is reported in Chapter 5.
4.2 Synthesis and purification2
We utilized previously reported syntheses for compounds 4.SM1306 and 4.SM2293,307
with minor modifications (Scheme 4.1). Synthesis of K2[RuCl5NO](4.SM1) was achieved by
refluxing RuCl3 · n H2O with K2NO2 in 0.5 M HCl, followed by addition of KCl and additional
refluxing. Pure dark pink-purple microcrystalline product was obtained (48% yield) after
evaporation of the solvent. K3[(H2O)Cl4Ru(µ-N)RuCl4(H2O)] (4.SM2) was obtained by
treatment of the aforementioned ruthenium nitrosyl with SnCl2 in HCl at reflux for an hour.
1This is the electrolytic conductivity, and is also referred to sometimes as the specific conductance.
However, for ease of this discussion it will simply be referred to as conductivity.
2Experimental details can be found in Appendix B.
60
Evaporation of the solvent afforded the product as red-brown crystals (38% yield).
Figure 4.1: Synthetic scheme for the formation of 4.SM2 from 4.SM1. Compound 4.SM1
was generated from RuCl3 · n H2O in the presence of acidic KNO2.
For characterization of these two products, the diagnostic IR spectroscopy and X-ray
crystal structure data was used. Crystals of 4.SM1 were obtained by slow evaporation of
an aqueous solution; the unit cell matched the previously reported structure.308 Compound
4.SM2 formed diffraction quality crystals by HCl diffusion into an aqueous solution; all X-
ray crystallographic parameters matched those previously reported (Figure 4.2a, Table 4.1,
Table B.2)).309,310 IR spectroscopy of the ammonium salt of 4.SM1 contained the diagnostic
NO stretch at 1894 cm−1 (Figure 4.2b).306 In addition, IR spectroscopy of 4.SM2 showed
the diagnostic asymmetric Ru-N-Ru stretch at 1078 cm−1 (Figure 4.2b), consistent with pre-
viously reported values.294 IR spectroscopy proved to be a useful tool for the characterization
of these complexes because of the characteristic Ru-N-Ru IR stretch. These values typically
range between 1000 and 1100 cm−1.297,310,311
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(a) (b)
Figure 4.2: The X-ray crystal structure of (a) 4.SM2 and (b) infrared spectra of 4.SM1
and 4.SM2.
Heating 4.SM2 in concentrated ammonia (d = 0.88) for six hours resulted in the substi-
tution of the equatorial chlorides with NH3 afforded an orange solution (Scheme 4.3). After
rotary evaporation, the addition of concentrated HCl to an aqueous solution of the crude
compound yielded a pale orange compound after cooling the solution overnight. Recrystal-
lization of this crude material by acetone diffusion into aqueous solutions yielded pure 4.1
with elemental composition consistent with 8 NH3, 2 Ru, 5 Cl, 1 N and 1.5 H2O. This
procedure varied slightly from the previously reported synthesis; the reaction is heated for a
longer period of time and was recrystallized from acetone after the initial HCl precipitation.
Compound 4.1 was found to be somewhat soluble in water and poorly soluble in DMSO;
gentle heating and sonication facilitated dissolution.
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Figure 4.3: Synthetic scheme for 4.1-4.5 from 4.SM2.
Similarly, dissolving 4.SM2 in 33% aqueous ethylenediamine (en) for one hour results
in the substitution of the equatorial chlorides with four en ligands to form compound 4.2
(Scheme 4.3). Isolation of the complex was achieved by precipitation with copious ethanol,
centrifugation, reconstitution with water and recrystallization with the addition of concen-
trated HCl to form the pure product in 28% yield. Compound 4.2 was found to be poorly
soluble in water and insoluble in organic solvents. Single crystals as needles were grown from
diffusion of HCl vapors into aqueous solutions of 4.2.
A previously described reaction of 4.SM2 with bpy reportedly gave the cation
[Ru2N(bpy)4(Cl)2]
3+, which was characterized only by IR spectroscopy and elemental anal-
ysis.294 3Substitution with 2,2’-bipyridines was affected by treatment with an excess of 2,2’-
bipyridine (bpy), 4,4’-dimethyl-2,2’-bipyridine (dmbpy), and 4,4’-dimethoxy-2,2’-bipyridine
(dmobpy) in an acetone-water mixture to form crude compounds 4.3, 4.4 and 4.5, respec-
3Thanks to Julie Urgiles for performing the synthesis and characterization of these complexes.
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tively. Upon recrystallization of the crude products from N,N -dimethylformamide (DMF),
red crystals of each compound were isolated in 16%, 3.5% and 5.3% yield, respectively. The
low yields are attributed to the low solubility of the complexes in DMF and a variety of side
products that could not be isolated in pure form. Yields could be increased by additional ex-
traction from the crude DMF mixture as discussed in the experimental section in Appendix
B.
4.3 Characterization results and discussion4
4.3.1 X-ray crystallography
Single crystals of 4.1 suitable for X-ray diffraction were extremely difficult to grow;
the complex is only minimally soluble in water and DMSO. Crystallization attempts from
many different solvent systems yielded either microcrystals or powders. Initial formation
of diffraction quality crystals was achieved by treatment of the complex with excess AgBF4
to form the BF4
– salt. After filtration to remove AgCl, ethanol diffusion into the solution
afforded single crystals. However, the X-ray structure indicated the counterion was the
octahedral SiF6
2−, as apposed to the expected tetrahedral BF4 – . This unexpected counterion
swap has been previously reported for a platinum complex.312 The BF4
– anion can hydrolyze
to form HF, which then can further react with SiO2 in the glass reaction vessel to form
SiF6
2−. The intentional treatment of an aqueous solution of 4.1 with (NH4)2SiF6 followed
by ethanol diffusion afforded crystals (4.1SiF6, Figure 4.4a), with the same structure as the
“accidental” formation, confirming the identity of the SiF6
2− counterions.
4Relevant bond distances and angles in Appendix B.
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(a) (b)
Figure 4.4: The X-ray crystallographic structures of (a) [(H2O)(NH3)4Ru(µ-
N)Ru(NH3)4(HO)](SiF6)2 and (b) [Cl(en)2Ru(µ-N)Ru(en)2Cl] grown from diffusion of
ethanol into water containing NH4SiF6 and deionized water solutions at room temperature,
respectively. Thermal ellipsoids are at the 50% probability level.
Compound 4.1SiF6 crystallized into the monoclinic space group I2/m. The µ-nitrido
nitrogen is located on 2/m special position. Thus the equatorial ammine ligands are eclipsed
and the Ru-N-Ru bond angle is exactly 180° (Table 4.1). A mirror plane bisects the molecule
along the Ru-N-Ru bond. Rotational disorder is observed in the ammines that sit on the
mirror plane, as well as the fluorines of the SiF6
2− counterions. Analysis of the bond angles
of the equatorial positions shows that the ammines bend slightly away from the µ-nitrido,
with the µ-N–Ru–NH3 angle averaging 94.6°. The ruthenium–µ–nitrido distance is 1.737
A˚, whereas the ruthenium-ammine distance is 2.102 A˚. Inspection of the intermolecular
interactions between neighboring cations show a close contact between axial oxygens of
neighboring molecules of 2.538 A˚ by expansion of the hydrogen bonding network in the
lattice. The two oxygens are related via a crystallographic inversion center; moreover, the
distance is too short to constitute normal hydrogen bonding interactions. We hypothesize
this is a symmetric hydrogen bond, where the atom is shared between the donating oxygen
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atoms. The second hydrogen could not be found in the electron difference map. However
based on the complex charge balance we assign the axial ligands as mixed hydroxide and
water. This is similar to our previous work (see Chapter 3) on an analog of Ru360 which had
a similar hydrogen bonding network and a mixed hydroxide/water axial ligand system.223
Table 4.1: X-ray crystallographic data collection and refinement parame-
ters for K3[Ru2NCl8(H2O)2], [(OH)(NH3)4Ru(µ–N)Ru(NH3)4(OH2)](SiF6)2 and
[Cl(en)2Ru(µ–N)Ru(en)2Cl]Cl3.
Crystal Data K3[Ru2NCl8(H2O)2] [(OH)(NH3)4Ru(µ–N) [Cl(en)2Ru(µ–N)
Ru(NH3)4(OH2)](SiF6)2 Ru(en)2Cl]Cl3
Formula Weight 653.08 668.6 649.82
Temperature/K 223 223 100
Crystal System Monoclinic Monoclinic Hexagonal
Space Group C 2/m I 2/m P6522
a/A˚ 15.8583(16) 7.5926(7) 10.0036 (1)
b/A˚ 7.4075(5) 15.6754(14) 10.0036 (1)
c/A˚ 8.1957(6) 9.5465(12) 37.9277(3)
α/° 90 90 90
β/° 121.115(2) 98.780(4) 90
γ/° 90 90 120
Volume (A˚3) 824.24(12) 1122.9(2) 3287.00(8)
Z 2 2 6
D, g cm−1 2.632 1.977 1.97
µ (mm−1) 3.868 1.563 16.94
Observed reflections 1185 6861 2088
Parameters 48 93 119
R1 (I >2σ))a 0.0163(1129) 0.0229(1560) 0.0168(2069)
wR2 (I>2σ)b 0.0349(1178) 0.0603(1709) 0.043(2088)
GOFc 1.089 1.114 1.07
Wavelength 0.71073 0.71073 1.54184
aR1 = Σ||Fo|-|Fc||/Σ|Fo|. bwR2 = {Σ[w(F 2o − F 2c )2]/Σ[w(F 2o )2]}1/2.
cGOF = {Σ[w(F 2o − F 2c )2]/(n− p)}1/2.
Complex 4.2 crystallized as orange needles in the hexagonal space group P6522 (Figure
4.4b). The ethylenediamine ligands show the canting typical for a 5-membered nonplanar
chelate ring. This canting can be characterized by δ or λ configurations (Figure 4.5).313,314
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Figure 4.5: The ethylenediamine ligand orientation of compound 4.2. δ or λ configuration
possibilities are shown, with the assignment of λ in grey.
Complex 4.2 crystallized with both ruthenium centers in the λ configuration.
The ethylenediamine ligands are staggered in the equatorial positions and chlorides are
on the axial positions (Figure 4.4b). The staggered conformation is different than the crystal
structure of 4.1SiF6 and 4.SM2; both of these compounds show an eclipsed conformation.
The substitution of ethylenediamine ligands on K3[Ru2NCl8(H2O)2] has been previously
reported.294,295 The reported X-ray crystal structure has five en ligands, with one of the
ligands bridging between the two ruthenium centers. In contrast to this reported structure,
we observe a symmetric system around each ruthenium with four en ligands instead of five
en ligands. The Ru-N-Ru bond angle is slightly bent, 176.36°, and is comparable to the
reported en substituted complex with a Ru-N-Ru bond angle of 174.6° (Table B.4). A two-
fold axis through the Ru-µ-N-Ru relates the ethylenediame ligands. Similar to compound
4.1SiF6, the ligands are slightly pushed away from the bridging center, ∼95° on average
and the Ru-N µ-nitrido distance is 1.759 A˚, whereas the Ru-N en-nitrogen distance is 2.105
A˚. In the five-en reported complex, the Ru-N µ-nitrido distances was 1.742 A˚ and the Ru-N
en-nitrogen equatorial distance was 2.113 A˚.
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Table 4.2: X-ray crystallographic data collection and refinement parameters for
[Ru2N(bpy)2Cl5(DMF)] and [Ru2N(dmobpy)2Cl5(DMF)]
Crystal Data [Ru2N(bpy)2Cl5(DMF)] [Ru2N(dmobpy)2Cl5(DMF)]
Formula Weight 778.86 898.97
Temperature/K 100.00(10) 100.01(10)
Crystal System Triclinic Triclinic
Space Group P1¯ P1¯
a/A˚ 9.79250(10) 12.2823(3)
b/A˚ 11.28330(10) 12.5160(2)
c/A˚ 15.4471(2) 15.2094(2)
α/° 77.1190(10) 98.4980(10)
β/° 84.0320(10) 106.815(2)
γ/° 71.1160(10) 111.247(2)
Volume (A˚3) 1573.34(3) 2000.61(7)
Z 2 2
D, g cm−1 1.644 1.492
µ (Mo Kα), mm−1 1.411
µ (Cu Kα), mm−1 9.518
Observed reflections 5961 7570
Parameters 336 412
R1 (I >2σa 0.0170 0.0257
wR2 (I>2σ)b 0.0407 0.0698
GOFc 1.015 1.075
Wavelength 0.71073 1.54184
aR1 = Σ||Fo|-|Fc||/Σ|Fo|. bwR2 = {Σ[w(F 2o − F 2c )2]/Σ[w(F 2o )2]}1/2.
cGOF = {Σ[w(F 2o − F 2c )2]/(n− p)}1/2.
Single-crystals of 4.3 were grown from a DMF solution and analyzed analyzed by X-ray
diffraction. The crystal structure of 4.3 conclusively reveals it to be [Ru2N(bpy)2Cl5(DMF)]
(Figure 4.6a) with the linear Ru-N-Ru moiety intact. The complex is asymmetric; one
ruthenium possesses an octahedral coordination geometry fulfilled by a bpy ligand, three
chlorides, and the bridging nitrido, while the other octahedral ruthenium center is coordi-
nated by a bpy ligand, two chlorides, a DMF solvent molecule, and the bridging nitrido.
This geometry is quite different than two previously reported products.294,297 The reaction
product of K3[Ru2NCl8(H2O)2] with bpy is reported as the complex [Ru2N(bpy)4(Cl)2]
3+.294
However, this report is only characterized by infrared spectroscopy and elemental analysis.
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A different reported structure with bpy substitution on the Ru-µ-N-Ru backbone has two
bipyridine ligands occupying an equatorial binding site on each ruthenium, shown by X-ray
crystallography. This was accessed by the high temperature reaction of [Ru(bpy)(CO)2Cl2]
in HCl-HNO3 mixtures.
297
(a) (b)
Figure 4.6: The X-ray crystal structures of (a) [Ru2N(bpy)2Cl5(DMF)] and
(b)[Ru2N(dmobpy)2Cl5(DMF)]grown from diffusion of methanol into dimethylformamide at
room temperature.
The crystal structure of 4.5 (Figure 4.6b) reveals the same stereochemistry that is present
in complex 4.3. Crystallographic refinement parameters and relevant interatomic distances
and angles are collected in Tables 4.2 and B.5. The Ru-N nitrido distances are slightly
asymmetric and vary from 1.7219(18) to 1.7375(18) A˚. No significant deviations in these
distances between the two compounds are noted, and the distances are similar to those
found in previously reported dinuclear nitrido-bridged complexes.295,297,298 The Ru-N-Ru
angles, which deviate slightly from 180°, are 173.10(9)° and 177.27(11)° for 4.3 and 4.5,
respectively. The equatorial and axial Ru-ligand interatomic distances are disparate. For
example, the Ru-N2 distance for the axial bpy ligand (2.1626(14) and 2.1546(19) A˚ for
4.3 and 4.5, respectively) is approximately 0.1 A˚ longer than the corresponding equatorial
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distances, which are between 2.0532(14) and 2.0646(18) A˚. The elongation of the axial bond
distances was most likely a consequence of the strong trans influence of the bridging nitrido
ligand. Crystals of compound 4.4 were successfully grown, however could not be analyzed
via X-ray diffraction due to twinning issues.
4.3.2 Spectroscopic characterization
UV-vis spectroscopy
The UV-vis spectrum of 4.1 in water shows 3 major transitions: 250 nm, 264 nm, 322
nm (Figure 4.7a). Compound 4.2 in water has a similar spectrum, with transitions at 239
nm, 274 nm, and 323 nm (Figure 4.7b, Table 4.3). The similarity in electronic spectra
between these two complexes suggests that the transitions arise from the orbitals involved in
the Ru-(µ-N)-Ru bridge. TDDFT analysis corroborates this hypothesis. The most intense
transition for both 4.1 and 4.2 (264 nm or 274 nm, respectively) is from the axial ligands
to the Ru-N-Ru backbone (Figures 4.7). For these two complexes, the axial ligands are
chlorides – the energies of the LMCT5 transition are quite similar.
5Ligand-to-metal charge transfer
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(a) (b)
Figure 4.7: The experimental UV-vis absorption spectra in pH 7.4 PBS and calculated
UV-vis spectra by TDDFT analysis. Calculated electronic transitions are illustrated
by going from dark red to light green. (a) [Cl(NH3)4Ru(µ–N)Ru(NH3)4Cl]Cl3 and (b)
[Cl(en)2Ru(µ–N)Ru(en)2Cl]Cl3
The UV-vis spectra of the compounds 4.3, 4.4, and 4.5 in dimethyl sulfoxide (DMSO)
(Figure 4.8 and Table 4.3) exhibited low-energy transitions between 350 and 380 nm, and a
higher energy transition near 300 nm. The low-energy transition is assigned as a metal-to-
ligand charge transfer by analysis of the orbital contributions calculated by TDDFT. The
energy of this transition shifts noticeably as the substituents on the bpy ligands are altered
through 4.3, 4.4, and 4.5.
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Figure 4.8: The experimental UV-vis absorption spectra in DMSO of [Ru2N(bpy)2Cl5(DMF)]
(solid black line), [Ru2N(dmbpy)2Cl5(DMF)] (red dash-dot-dot line) and
[Ru2N(dmobpy)2Cl5(DMF)] (blue dash line).
As more electron-donating groups are introduced, the MLCT6 energy shifts to higher energy.
This result is consistent with the effect of electron donating groups, which increase the energy
of the accepting ligand pi* orbital of the diimine ligand.315
Table 4.3: Extinction coefficients for compounds 4.1 and 4.2 complexes taken in pH 7.4 PBS
and compounds 4.3, 4.4 and 4.5 in DMSO. Units in [M−1cm−1] and wavelength maxima
[nm] in parentheses
Compound 4.1 Compound 4.2 Compound 4.3
9400 ± 820 (232) 9400 ± 240 (238) 29000 ± 200 (299)
32000 ± 3300 (265) 32000 ± 660 (274) 8200 ± 100 (381)
1400 ± 80 (322) 1700 ± 45 (322)
Compound 4.4 Compound 4.5
20400 ± 800 (298) 35000 ± 4000 (392)
6000 ± 300 (376) 10200 ± 900 (368)
IR spectroscopy
A diagnostic feature in nitrido-bridged ruthenium complexes is the asymmetric Ru-N-Ru
stretching mode. The infrared spectrum of 4.1SiF6 reveals the Ru-(µ-N)-Ru stretch to be at
6Metal-to-ligand charge transfer.
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1061 cm−1. This feature was assigned by exchanging the NH oscillators with ND oscillators.
The exchange was accomplished by dissolving the compound in D2O and lyophilization of
the solvent. Comparison of the IR spectrum of compound 4.1 to 4.1SiF6 show consistent
vibrations, with additional modes due to SiF6
2− at 694 cm−1. Of note, however, is a 17
cm−1 energy difference for the Ru-N-Ru stretching mode between 4.1 and 4.1SiF6. We at-
tribute this shift due to 4.1 and 4.1SiF6 containing axial chlorides and waters, respectively.
DFT calculations of the vibrational frequencies of the two compounds revealed the same
difference; the presence of axial waters increasing the Ru-N-Ru vibrational energy. We also
see differences in the ammine stretches between 4.1 and 4.1SiF6 which we also attribute
to the small change in the hydrogen bonding network caused by the replacement of chlo-
ride to water in the axial position. The axial water can hydrogen bond with the equatorial
ammines, slightly reducing the observed vibrational energy. This same shift is observed in
the vibrational frequency DFT calculations. Morover, reports of 4.SM2 indicate counterion
dependent small shifts in the IR spectrum. This suggests that upon counterion substitution
from chloride to hexafluorsilicate for compound 4.1 we would expect some changes.316
Compound 4.2 has a more complex IR spectrum in fingerprint region due to the addi-
tional modes from the C-H bonds (Figure 4.9b). The sharp feature at 1055 cm−1 is likely
the Ru-N-Ru stretch, consistent with the previously reported datum for this complex.294
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(a) (b)
Figure 4.9: The infrared spectra of (a) hydrogen, deuteron, and SiF6 form of compound 4.1
and (b)[Cl(en)2Ru(µ–N)Ru(en)2Cl]Cl3 (4.2) and [Ru2N(bpy)2Cl5(H2O)] (4.3). The arrow
points at the Ru-N-Ru asymmetric stretch.
Similar to compound 4.2, the conclusive identification of the asymmetric stretching mode
in the IR spectrum of 4.3, 4.4, and 4.5, however, was challenged by the presence of lig-
and vibrational features within this region (Figure 4.9b). Absorbance bands at 1030 and
1074 cm−1, 1032 and 1065 cm−1, and 1030 and 1063 cm−1, are tentatively assigned as the
symmetric and asymmetric Ru-N-Ru stretching frequencies in 4.3, 4.4, and 4.5, respec-
tively. These values are consistent with previously reported all-equatorial bpy complex,
[Ru2N(bpy)2Cl5(H2O)], suggesting that the stereochemical arrangement of these ligands has
little effect on the ruthenium-nitrido bond.294
NMR spectroscopy
Compound 4.SM2 was reported to be diamagnetic with a magnetic susceptibility of
–6.3×10−6 c.g.s.u.292 The NMR spectra revealed that compounds 4.1, 4.2, 4.3, 4.4, and
4.5 were all diamagnetic as expected for RuIV/RuIV systems. The 1H NMR spectrum of
4.1 in DMSO-d6 had a single peak at 4.14 ppm corresponding to the ammine N-H protons.
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The presence of a single peak is indicative of a symmetric complex; no additional signals
are observed. Compound 4.2 had a 1H NMR spectrum that showed two multiplets at 2.69
ppm and 3.10 ppm, relative to 1,4-dioxane in D2O, corresponding to the C-H protons. The
ammine protons are at 5.16 ppm and 5.32 ppm and decay in intensity over time (t1/2 = 72.6
min) as the N-H protons exchange with deuterium. The two C-H protons on each carbon
of the ethylenediamine were not symmetric due to the cant and restricted movement of the
5-membered chelate ring (Figure 4.5). The canting results in the CH2 protons appearing as
a doublet. Similarly, the ammine N-H protons were also a doublet. The 13C NMR spectrum
had one signal at 46.44 ppm, indicative of a symmetric spin system (Figure B.2). This is
in contrast to the reported µ-nitrido complex with five en ligands; the authors reported an
asymmetric spin system with five 13C signals.295
(a) (b)
Figure 4.10: The NMR spectra of (a) compounds 4.1 and 4.2 in DMSO-d6 and D2O, re-
spectively and (b) compound 4.3 in DMSO-d6.
1H NMR spectroscopy of compounds 4.3, 4.4 and 4.5 revealed three distinct aro-
matic spin systems similar to 4.3 (Figures 4.10b and B.4-B.9). Previously reported
nitrido-bridged dinuclear ruthenium complexes bearing bpy ligands, [Ru2N(bpy)2Cl5(H2O)]
and (H5O2)[Ru2N(bpy)2Cl6] were isolated from the high temperature reaction of
[Ru(bpy)(CO)2Cl2] in HCl–HNO3 mixtures and were structurally characterized by X-ray
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crystallography.297 These structures both showed a single bpy ligand coordinated in a biden-
tate manner to each ruthenium center. The orientation of the bpy ligands were such that both
nitrogen donor atoms reside in a cis disposition on the equatorial plane, in the cis disposition
relative to the bridging nitrido ligand. Although the 1H NMR spectra of these complexes was
not reported, symmetric spectra would be expected given the chemical equivalence of the two
bpy ligands. By contrast, the 1H NMR spectrum of compounds 4.3, 4.4 and 4.5 reveal three
distinct sets of aromatic spin systems in a ratio of 2:1:1 (Figure 4.10b), indicating that we had
isolated a less symmetric compounds than the previously reported [Ru2N(bpy)2Cl5(H2O)],
(H5O2)[Ru2N(bpy)2Cl6], and [Ru2N(bpy)4(Cl)2]
3+ complexes. Lastly, free DMF signals were
present in the 1H NMR at 7.95, 2.89, and 2.73 ppm, corresponding to uncomplexed solvent,
suggesting the axial position is relatively labile to substitution.
Cyclic voltammetry
The electrochemical properties of 4.3, 4.4, and 4.5 were investigated by cyclic voltamme-
try (Figure 4.11). Anodic scans revealed the presence of a quasi-reversible oxidation feature,
which is tentatively attributed to the RuVRuIV/RuIVRuIV couple. In related nitrido-bridged
dinuclear complexes, the RuVRuIV state could be accessed at relatively mild potentials, sig-
nifying the ability of the nitrido ligand to stabilize high oxidation states.302–304 This quasi-
reversible oxidation (E1/2) to the Ru
VRuIV state occurs at 1.33, 1.25, and 1.19 V vs SCE for
4.3, 4.4 and 4.5, respectively, demonstrating that the donating methyl and methoxy groups
on 4.4 and 4.5 stabilize the higher oxidation states.
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Figure 4.11: The cyclic voltammetry profiles of compounds 4.3, 4.4, and 4.5.
Upon scanning cathodically, an irreversible reduction feature is observed, which is ten-
tatively assigned to the RuIVRuIV/RuIVRuIII couple. The peak potentials (Ep) of this irre-
versible reduction are –1.03, –1.10, and –1.22 V vs SCE for 4.3, 4.4, and4.5, respectively. As
expected, these values indicate that reduction occurs at more positive potentials when the
bpy ligand has less electron-donating substituents. Upon cycling back to anodic potentials,
a new quasi-reversible oxidation feature, presumably arising from the irreversible reduction
product, is observed. Notably, the E1/2 of this quasi-reversible oxidation is relatively invari-
ant for the three complexes: 0.95 V vs SCE. This result suggests that this oxidation might
arise from a ruthenium-containing product that lacks the diimine ligands.
4.3.3 Solution reactivity
Ru360 was found to undergo aquation at the axial positions with the formate groups
replaced by aquo ligands.233 The corresponding Cl/Cl complex, with chlorides instead of
formates, was also observed to undergo aquation. This reaction is most likely a two-step
process, where one axial ligand is substituted by water and then the second one. However,
only one rate constant was observed and thus the data was treated as a single-step process
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that was first-order with respect to ruthenium. The aquation was observed to be pH depen-
dent, with a maximum rate constant of ∼8×10−3 sec−1 (t1/2 = 1.4 min) at pH 1 slowing to
∼2×10−4 sec−1 (t1/2 = 58 min) at pH 7 for the aquation of both the formate species and
the chloride species.
Compounds 4.3, 4.4, and4.5 did not have an observed solution state structure, other than
the labile DMF axial ligand observed by 1H NMR spectroscopy. Compound 4.1 exhibited a
time-dependent change in the UV-vis spectrum. In pure water, the main spectral feature at
265 nm underwent a blue shift to 256 nm (Figure 4.12a). Plots of ln[(A0 −A)/(At −A)] vs
time were linear, indicating a first order kinetic process, where A0 is the initial absorbance,
At is the absorbance at time t and A is the equilibrium absorbance.
317 The observed first
order rate constant (kobs) in pure water was 1.9×10−4 ± 8.8×10−6sec−1 (t1/2 = 60 min), fit
to the equation[(A0−A)/(At−A)] = exp(−kobst). There were three well-resolved isosbestic
points in pure water at 315 nm, 292 nm and 234 nm, indicating that this reaction proceeds
without any long-lived intermediates. The rate constant was similar to those measured for
the aquation of other ruthenium complexes.233,317,318
Tracking the pH reveals a decrease in the pH from ∼8 to ∼4. This suggests the aquation
process includes the loss of an equivalent of HCl and therefore most likely pH dependent.
Additionally, the aquation was found to be highly dependent on the buffer utilized. At pH
7.4, three different UV-vis spectral features were observed with three different buffers (Figure
4.12b) In 0.1 M MOPS7, almost no spectral changes were observed, while in 0.1 M Bis-Tris
the process appeared to reach equilibrium (Figure 4.12b, left). In 0.1 M potassium phosphate
buffer, the aquation appeared to proceed but a new product grew in, potentially a phosphate-
bound complex. At very low pH (1-3.5) in HClO4 acid a biexponential spectral change
8 is
observed (Figure 4.12b, right). The two observed rate constants are most likely from each
73-(N -morpholino)propanesulfonic acid
8abs = c1(e
−k1t) + c2(e−k2t) + c3 where cn are coefficients and k1 and k2 are first order rate constants
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of the two aquation steps. The first rate constant (k1) is is 9.1×10−4 ± 4.1×10−4 sec−1 (t1/2
= 12 min) and the second (k2) is 6.3×10−5 ± 9.8×10−6 sec−1 (t1/2 = 183 min) between
pH 1 and 3.5 in HClO4. This reaction is significantly slower than the aquation observed
for Ru360. Above pH 5 the UV-vis kinetic traces were consistently more complex, without
clean isosbestic points or spectral shifts. The complexity suggests that as the hydroxide
concentration increases additional mechanisms are accessed leading to more complex spectra.
(a) (b)
Figure 4.12: (a) The solution state change of compound 4.1 in pure H2O by conductance
(subfigure a) and UV-Vis (main and subfigure b). (b) Buffer dependence at pH 7.4 for the
aquation process and a representative trace for the aquation in HClO4 (pH 2) for compound
4.1.
As the chloro ligands are substituted for aquo, it is expected the electrical conductivity
will increase as the charge of the complex will increase from +3 to +5. Indeed, this was
observed in a time dependent manner (Figure 4.12a) with a first order rate constant of
1.8×10−4 ± 8.1×10−6 sec−1 (t1/2 = 64 min). This was almost identical to the rate constant
in H2O observed by UV-vis. Due to the instability of the complex to aquation, analysis
of the initial compound using the Debye-Hu¨ckel-Onsager equation could not be obtained
on the initial solutions. This equation describes the relationship between concentration
(c) and conductivity in very dilution solutions: Λ = Λ0 − K
√
c, where Λ is the measured
molar conductivity, Λ0 is the infinite dilution conductivity, and K is a constant that is
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proportional to Λ0, the ionic charge and the ionic strength.
319,320 For the stable equilibrium
product of compound 3.1 an infinite dilution conductance of 997 S·cm2/mol was measured.
As the electrolyte number increases, the conductance will also increase, ranging from 150-250
S·cm2/mol, depending on the electrolyte.320 K4[Fe(CN)6], a 4:1 electrolyte, had an infinite
dilution conductance of 740 S·cm2/mol. A 5:1 electrolyte would be expected to have a higher
Λ0. This will put the range for 5:1 electrolytes around 900-1000 S·cm2/mol. Aquation of
compound 4.1 would result in increased charge from +3 to +5, which was consistent with
the observed data.
Moreover, the fully aquated product would have a symmetric 1H NMR signature. The
equilibrium product from the aquation of compound 4.1 was isolated by the lypohilization
of an aged, aqueous solution. The 1H NMR spectra of the equilibrium product indicated the
formation of a new species. This new compound contains only one NMR signature, a singlet
at 4.24 ppm, consistent with a new symmetric product. In the case of single aquation, with
one aquo axial ligand and one chloro, an asymmetric signature would be expected. Both the
new NMR signature, and the increased conductivity, are observed in the equilibrium product
of 4.1. Thus we conclude compound 4.1 underwent complete aquation.
Compound 4.2 was isolated with chlorides in the axial positions confirmed by X-ray
crystallography (Figure 4.4b). Similar to compound 4.1, the change can be observed by
NMR, UV-vis and conductivity. Integration of the 1H NMR peaks indicated only about
20% conversion (Figure 4.13a). The C-H protons from the en ligand occurred at 2.69 and
3.10 ppm. However, in an aged solution two additional peaks appeared at 2.76 and 2.96
ppm with the same symmetric spin system as the original two C-H signals. To verify these
smaller signatures as the diaquated product, a little AgOTf was added to the NMR tube.
The silver will react with the Cl– to form insoluble AgCl. Water will quickly add in the axial
positions, thereby forming the diaqua complex. After the addition of AgOTf the peaks at
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2.96 and 2.76 ppm quickly grew in intensity while the peaks at 2.69 and 3.10 ppm decreased
in intensity. This revealed that the observed signals were in fact from the Cl/Cl complex
and the H2O/H2O complex. The asymmetric Cl/H2O system was not observed in the
1H
NMR.
(a) (b)
Figure 4.13: (a) Equilibrium 1H NMR spectrum of compound 4.2 (b) The solution state
change of compound 4.2 in pure H2O by UV-Vis (subfigure a) and conductance (subfigure
b).
The time-dependent conductance of compounds 4.2 reveals an observed rate constant
of 2.5×10−4 sec−1 (t1/2 = 46 min) (Figure 4.13b). The UV-vis undergoes a blue shift from
274 nm to 267 nm. Tracking the decrease in the absorption at 274 nm over time reveals a
rate constant of 3.0 ×10−4 sec−1 (t1/2 = 39 min), similar to the rate constant observed by
conductance. A fresh aqueous solution has a molar conductance of 368.1±13.48 S·cm2/mol,
consistent with the +3 charge expected from the crystal structure.321 From these data, we
conclude that compound 4.2 undergoes incomplete aquation, reaching equilibrium at ∼20%
formation of the H2O/H2O product.
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4.4 Conclusion
In summary, the synthesis and characterization of five diruthenium µ-nitrido complexes
are described. These complexes are prepared starting from K3[Ru2NCl8(H2O)2]. X-ray
crystal structures revealed ligand substitution on the equatorial positions for compound 4.1
and 4.2, however an asymmetric bonding for compounds 4.3 and 4.5. Compounds 4.1 and
4.2 have UV-vis spectrum dominated by LMCT transitions, while compounds 4.3, 4.4, and
4.5 are dominated by MLCT transitions. Infrared spectroscopy revealed consistent Ru-N-Ru
stretching modes which are diagnostic for this class of compounds. NMR spectroscopy was
consistent with the symmetric and asymmetric environment for each respective complex. In
aqueous solutions compound 4.1 and 4.2 underwent aquation in the axial positions, observed
by changes in the UV-vis spectrum, conductance and 1H NMR. Future directions for these
systems include exploring detailed kinetics for compounds 4.1 and 4.2. In addition, exploring
axial ligand substitutions as well as different equatorial ligands can be used to build a library
of similar complexes.
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CHAPTER 5
BIOLOGICAL INVESTIGATIONS
5.1 Introduction1
In additional to their application as catalysts, ruthenium complexes may also exhibit in-
teresting biological activity. NAMI-A and KP1019 (Figure 5.1a, 5.1b) are examples of ruthe-
nium based anti-cancer agents and have been advanced into the clinical trial stages.322–328
RAPTA-C, a complex of the organometallic ”piano-stool”-type family (Figure 5.1c), and
similar structural analogs have also been extensively explored for their anticancer proper-
ties.329–333
(a) (b) (c)
Figure 5.1: The structure of three of the most common ruthenium anti-cancer complexes
under investigation: (a) NAMI-A, (b) KP1019 and (c) RAPTA-C
RuRed, discussed earlier in chapter 2, has been used as a cellular stain due to
its high charge and intense color. It also inhibits mitochondrial calcium uptake along
1Chapter reproduced in part with permission from Inorg. Chem., 2017, 56(6), pp 3123 - 3126. Copyright
2017, American Chemical Society.
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with Ru360 (see Chapter 2). Due to their low toxicities and potent MCU inhibitory
properties, these compounds have been investigated as potential therapeutics for low-
ering the effects of ischemia-reperfusion injury.192,193,249–252,255,259–261,334 We were inter-
ested in expanding the library of MCU inhibitory complexes with similar structural
frameworks as Ru360 to explore potential structure-activity relationships, and thereby
understand the mechanism of action. In this vein, we synthesized and character-
ized several structural analogs of Ru360 (see Chapters 3 and 4): [(OH2)(NH3)4Ru(µ-
O)Ru(NH3)4(OH2)]
5+ (3.1), [Cl(NH3)4Ru(µ-N)Ru(NH3)4Cl]
3+ (4.1). [Cl(en)2Ru(µ-
N)Ru(en)2Cl] (4.2), [(DMF)Cl2(bpy)Ru(µ-N)Ru(bpy)Cl3] (4.3), [(DMF)Cl2(dmbpy)Ru(µ-
N)Ru(dmbpy)Cl3] (4.4) and [(DMF)Cl2(dmobpy)Ru(µ-N)Ru(dmobpy)Cl3] (4.5).
These structural analogs of Ru360 were tested for cell viability in HeLa cell. MCU
inhibition abilities were determined in permeabilized HeLa cells. Compounds found to
inhibit mitochondrial calcium uptake were further studied using isolated mitochondria
expressing the MCU in a variable dose manner to determine the 50% inhibitory con-
centration of calcium uptake. From these data three compounds were found to inhibit
the MCU: [(OH2)(NH3)4Ru(µ-O)Ru(NH3)4(OH2)]
5+, [Cl(NH3)4Ru(µ-N)Ru(NH3)4Cl]
3+ and
[Cl(en)2Ru(µ-N)Ru(en)2Cl]
3+. These three compounds were tested on both HeLa and
HEK293 cells for uptake and cytotoxicity. The most potent compound was found to be
4.1, and additional mechanistic studies with the D261A and S238A MCU mutants were
investigated.
5.2 Cellular toxicity
The MTT assay can be used to measure cell viability.335,336 The reduction of the yellow
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to the formazan salt,
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3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylformazan, (Figure 5.2) by mitochondrial reductase
produces purple crystals. The crystals only form in respiring (viable) cells and are soluble
in polar organic solvents, such as DMSO. Dose-dependent % viability is determined by
measuring the absorbance of the resulting formazan dye.
Figure 5.2: Reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylformazan (Formazan) catalyzed by mi-
tochondrial reductase.
Compounds 3.1, 4.1 and 4.2, were nontoxic in HeLa cells, with 50% viability inhibitory
concentrations (IC50) of 228 ±15 µM and 225±33 µM, for 4.1 and 4.2,respectively (Figure
5.3a). The three µ-nitrido complexes with bipyridine (4.3, 4.4, and 4.5) substitutions were
also nontoxic up to 20 µM (Figure 5.3b). However, due to solubility limitations of these
complexes, IC50 values could not be obtained. Compound 3.1 did not show consistent
cytotoxicity at high concentrations over four trials – in one trial at 400 µM there was not
100% cell death and one data set showed a full cell curve with an IC50 value of 290 µM. At
100 µM, the average cell viability was 67±13 % over four trials; this is most likely due to
the observed instability in biological media, as discussed in Chapter 3.
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(a) (b)
Figure 5.3: The cellular viabilities of the (a) oxo-bridged Ru360 analog, and the ammine and
ethylenediamine substituted nitrido complexes. (b) The cell viabilities of the three bipyridine
substituted nitrido bridged complexes in HeLa cells.
The cell viability was also considered in healthy kidney cells (HEK293). These were used
as a more accurate model for ischemia reperfusion injury in comparison to the HeLa cells as
kidneys are known to undergo IRI. HEK293 cells were found to have diminished adherence
to cell culture dishes when treated with ruthenium-containing complexes, in comparison to
untreated cells. Thus, single-dose cytotoxicity measurements were performed with a slightly
modified protocol. HEK293 cells were dosed with the three lead compounds, 3.1, 4.1 and
4.2, for 72 hr. The % viabilities were found to be 83%, 68% and 80% for compounds 3.1,
4.1 and 4.2, respectively. These complexes were all more cytotoxic in comparison with HeLa
cells, however could still be considered generally nontoxic.
5.3 Cellular uptake
Metallic complexes may enter cells via several different mechanisms. Passive diffusion,
or simple diffusion through the cellular membrane, is perhaps the simplest pathway, and
some metallic complexes are known to enter in this manner.337 However, this is less likely
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for charged complexes, such as NAMI-A or KP1019 (Figure 5.1) as their positive charges
impede progress through the anionic phospholipid membrane. These types of complexes
are more likely to enter via active transport, the second major mechanism for cellular up-
take. NAMI-A, for example, is not taken up by the cell efficiently and instead acts on
the cellular wall.338–340 Binding of serum proteins and ubiquitin by metal complexes may
prove to be an additional mechanism for cellular entry of ruthenium complexes.339,341–343
Transferrin is a serum protein that acts as an iron binder and transporter. After binding
the transferrin receptor, the protein enters the cell via endocytosis and the iron is reduced
and released into the cytosol.344,345 Although ruthenium complexes have been shown to bind
transferrin, whether or not this mediates ruthenium cellular uptake is a subject of continuing
research.289,324,326,338,339,346–355. Regardless of the mechanism, passive or active, the levels of
compound that enter the cell are critical in determining the efficacy of the compound of
interest.
KP1019 accumulates in SW480 (colon adenocarcinoma) cells at a concentration of 171 ±
7 pg/µg; Ru content in a variety of cell lines from short term dosage by KP1019 is around
500 pmol/106 cells.356,357 In A2780 cells dosed with KP1019, ruthenium levels in isolated
mitochondrial was 650 pg/µg, whereas in the related cisplatin resistant line, A2780cisR, the
Ru content was a factor of 3.7 lower. However, for NAMI-A, this value was close to 350
pg/µg, and there was not a significant difference between cell lines. This result suggests that
even for similar compounds the subcellular distribution is highly variable. Ruthenium is
not endogenous to biological systems. Therefore detection of complexes is amenable to ana-
lytical techniques such as atomic absorption spectroscopy, X-ray absorption or fluorescence
techniques, electron paramagnetic resonance spectroscopy and inductively coupled plasma
ionization techniques.346,356–363 Atomic absorption (AA) is one of the more common methods
due to its high sensitivity and ease of use.356,360
87
Table 5.1: Ru levels of lead compounds treated with 25 µM in HeLa and HEK293 cells.
Compound Cell Type Concentration
[pg Ru/µg protein]
Ru360 HeLa 75 ± 16
[(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
5+ HeLa 45 ± 3
[Cl(NH3)4Ru(µ–N)Ru(NH3)4Cl]
3+ HeLa 210 ± 83
[Cl(en)Ru(µ–N)Ru(en)Cl]3+ HeLa 96± 15
Ru360 HEK293 202 ± 23
[(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
5+ HEK293 123 ± 34
[Cl(NH3)4Ru(µ–N)Ru(NH3)4Cl]
3+ HEK293 327 ± 98
[Cl(en)Ru(µ–N)Ru(en)Cl]3+ HEK293 76 ± 43
To measure the cellular uptake of compounds 3.1, 4.1 and 4.2, the cells were cultured
for 24 h. The cells were then treated with 25 µM of each compound and incubated for
an additional 24 h. The cells were harvested, lysed, the protein content measured by the
Bradford assay, and the ruthenium content by AA. Treatment with 25 µM of compound
3.1 in HeLa cells showed complex uptake of 45 pg/µg Ru content per protein (Table 5.1).
Dosing HeLa cells with 4.1 and 4.2 showed Ru content per protein content of 210 and 96
pg/µg, respectively. In HEK293 cells, these levels were 123, 327 and 76 pg Ru/ µg protein
for 3.1, 4.1 and 4.2, respectively. Dosing with Ru360 had a Ru uptake concentration of 75
pg Ru/ µg protein in HeLa cells and 202 pg Ru/ µg protein in HEK293 cells (Table 5.1). A
plausible explanation in the difference between these compounds is the difference in charge.
The +5 charge of complex 3.1 maybe facilitate interactions with the anionic phospholipid
membranes. In comparison, the +3 charge of complex 4.1 will have less electrostatic in-
teractions with the membranes. However additional mechanisms may be operating since
the nitrido bridged complexes aquate at the axial positions, which will increase the complex
charge (+3 to +5, see Chapter 4). The low uptake of the ethylenediamine substituted system
(compound 4.2) was unexpected. Though of the same ionic charge as compound 4.1, the
slightly more lipophilic ligands appear to impact uptake significantly.
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5.4 Calcium uptake inhibition
For all the structural analogues to Ru360 and related starting materials, we verified the
mitochondrial calcium uptake inhibition properties. HeLa cells (7.5 × 106) were permeabi-
lized with digitonin and incubated with 2 µM of the turn-on calcium-responsive dye Calcium
Green-5N.118,364 The fluorescence response of the dye was monitored over time after the addi-
tion of 7.5-10 µM boluses of CaCl2. Addition of Ca
2+ ions leads to an immediate increase in
emission intensity, which decays over the course of 3-5 minutes as the Ca2+ ions are buffered
by the mitochondria (Figure 5.4a, blank). This process is reproducible for many (∼10) pulses
of Ca2+ ions, after which an overload of Ca2+ in mitochondria triggers the opening of the
permeability transition pore and leads to release of Ca2+ ions from the organelle.
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(a) (b)
(c) (d)
Figure 5.4: Calcium uptake inhibition using the Calcium Green-5N assay using perme-
abilized HeLa cells. The arrows indicate when the ruthenium complex is added in (b),
(c) and (d). (a) The response from the three methods to synthesize [(OH2)(NH3)4Ru(µ-
O)Ru(NH3)4(OH2)]
5+ (3.1), commercial Ru360 and no inhibitors present (blank). The
inhibitors were preincubated in the cuvette for 15 min before beginning the run. (b)
[Cl(NH3)4Ru(µ-N)Ru(NH3)4Cl]
3+ (4.1) and [Cl(en)Ru(µ-N)Ru(en)Cl]3+ (4.2) calcium up-
take inhibition; (c) Bipyridine substituted nitrido bridged complexes (4.3, 4.4 and 4.5),
with the ligand specified; (d) the lack of calcium uptake inhibition of two starting materi-
als and a potential metabolite. The asterisk indicates the addition of a calcium ion bolus.
Figure reproduced in part with permission from Inorg. Chem., 2017, 56(6), pp 3123 - 3126.
Copyright 2017, American Chemical Society.
The addition of 5 µM of 3.1, synthesized by the different methods outlined in Chapter 3,
to permeabilized HeLa cells inhibits mitochondrial calcium uptake (Figure 5.4a). A bolus of
Ca2+ gives rise to an increase in fluorescence intensity with no decay, as the mitochondrial
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calcium uptake is impaired. Commercially available Ru360 exhibits similar properties in
preventing mitochondrial calcium uptake (Figure 5.4a). Similar responses were seen with 4.1
and 4.2 (Figure 5.4b). However, the bipyridine substituted complexes, [Cl10Ru2(µ–O)] and
4.SM2 did not show any inhibitory properties (Figures 5.4c, 5.4d). trans-[(NH3)4Cl2Ru]
+
(synthesized by literature procedures365) was considered a potential active metabolite of
Ru360 and 3.1 decomposition. The breaking of the µ-oxo bond from decomposition would
release two mononuclear ruthenium species, with four ammine ligands in the equatorial plane,
similar to trans-[(NH3)4Cl2Ru]
+. However trans-[(NH3)4Cl2Ru]
+ did not inhibit calcium
uptake (Figure 5.4d), revealing this potential decomposition product is not active.
2To confirm the activity of the complexes on the MCU and not a different calcium trans-
porter, we utilized yeast mitochondria expressing the human pore-forming subunit MCU,
the essential regulator EMRE of the mitochondrial calcium uniporter, and a mitochondria-
targeted aequorin as a luminescence-based calcium sensor.168,185,366,367 Focusing on the com-
pounds determined to work in the permeabilized cells assay (3.1, 4.1, 4.2), we measured
the concentration-dependent inhibitory effect on calcium uptake. The dose-response curves,
fit with the Hill Equation, revealed the Michaelis constant (k), a measure of the effectiveness
of calcium uptake inhibition, for commercially available Ru360 to be 227 ± 20 nM (Figure
5.5a). Results for commercial Ru360 were notoriously inconsistent. Eight separate trials pro-
duced Michaelis constants between 466 nM and 153 nM, averaging to 279 ± 111 nM. This
may be due to uncharacterized impurities. Ru360 is known to undergo aquation at the axial
positions, therefore the differences in activity may be due to different levels of the aquated
product. The analogue 3.1 (method 1) was found to be more potent with a constant of 38 ±
16 nM while preparations via methods 2 and 3 afforded similar potencies of k = 48 ± 10 and
50 ± 20 nM, respectively (Figure 5.5a). Remarkably, although 3.1 and Ru360 differ only by
nature of the axial ligand, 3.1 demonstrates up to 10× greater inhibitory properties (Figure
2Thanks to Daniela Arduino in the group of Fabiana Perocchi for obtaining these data
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5.5a). 4.1 and 4.2 also only differ in equatorial ligands and have inhibitory constants of 26
± 3 nM and 1100 ± 50 nM, respectively (Figure 5.5b).
(a) (b)
Figure 5.5: Dose response of the mitochondrial calcium uptake in isolated yeast mitochondria
expressing the MCU (a) in the presence of Ru360, or 3.1 and (b) in the presence of Ru360,
4.1 or 4.2. Figure reproduced in part with permission from Inorg. Chem., 2017, 56(6), pp
3123 - 3126. Copyright 2017, American Chemical Society.
3We then investigated the ability of each complex to inhibit calcium uptake in non-
permeabilized cells. Non-permeabilized cells are more relevant to in vivo systems, taking
into account differences in uptake mechanisms. HeLa cells were cultured and incubated
with the cell permeant, mitochondrial targeting, calcium sensitive fluorescent dye Rho-2AM.
Mitochondrial calcium uptake was stimulated by the addition of histimine.368 Inhibition of
mitochondrial calcium uptake by compound 3.1 was found to be inconsistent across two
replicates and compound 4.2 did not show significant inhibition (Figure 5.6). However,
compound 4.1 was found to inhibit calcium uptake significantly. This data is consistent
with the Ru cellular uptake measurements. Compound 4.1 showed the most uptake in HeLa
cells, and had the highest MCU inhibitory ability. Compound 4.2 had the worst cellular
uptake and did not significantly inhibit mitochondrial calcium uptake.
3Thanks to Santhanam Shanmughapriya and Neeharika Nemani in the group of Madesh Muniswamy for
obtaining these data
92
Figure 5.6: Calcium uptake inhibition of [(OH2)(NH3)4Ru(µ-O)Ru(NH3)4(OH2)]
5+ (comp
3.1), [(Cl)(NH3)4Ru(µ-N)Ru(NH3)4(Cl)]
3+ (comp 4.1), and [Cl(en)Ru(µ-N)Ru(en)Cl]3+
(comp 4.2) in unpermeabilized HeLa cells measured by Rho-2 fluorescence. The variability
between trials can be seen for compound 3.1.
To further understand the mechanism of action of these complexes, two MCU mutants in
isolated yeast mitochondria and isolated HEK293 mitochondria were investigated. The first
study investigated the effect of the D261A mutant on inhibitor function. The D261 residue
has been established as a key residue responsible for inhibition with Ru360; mutation of this
residue to an alanine (D261A) will retain about 30% of protein function. However, the in-
hibitory ability of Ru360 is attenuated.185,369 Molecular docking studies of mitoxantrone and
Ru360 with the MCU showed significant hydrogen bonding interactions between this residue
and these inhibitors.185,186 To test the significance of the D261 residue on the mechanism of
action of our compounds, 4.1 and 4.2 were incubated4 in a dose-response manner with the
D261A mutant expressed in yeast mitochondria.
4Thanks to Daniela Arduino in the group of Fabiana Perocchi for this data
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(a) (b)
Figure 5.7: Dose response of the mitochondrial calcium uptake in isolated yeast mitochondria
expressing the D261A mutant MCU in the presence of (a) 4.1 and in the presence of (b)
4.2.
In the D261A mutant compound 4.1 is ineffective (Figure 5.7a). Compound 4.2 was also
tested on the D261A MCU mutant – the effect was similar (Figure 5.7b). This reveals that
compounds 4.1 and 4.2 inhibit by interacting with the same aspartate (A261) residue as
Ru360.185
The the S238A mutant has a similar effect as the D261A mutant – the protein function is
maintained but Ru360-induced calcium inhibition is attenuated.189 Hydrogen bonding was
also observed between Ru360 and S238 in the aforementioned docking studies.186
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Figure 5.8: Inhibition of calcium uptake in HEK293 cells after mutation of the conserved
serine to alanine; control: calcium uptake with no inhibitor
5Under constant concentration of compound 4.1 (10 nM) or Ru360 (500 nM) the S259A
mutant showed a similar affect as the D261A mutant. The S259A and S238A are same
residue, the difference in residue number is due to the differences in sequence between organ-
isms. S238 is from the C. elegans MCU and S259 is from human-derived MCU. The S259A
MCU had decreased protein function, however the inhibitors were less effective at blocking
mitochondrial calcium uptake (Figure 5.8).
5.5 Conclusion
A number of dinuclear µ-nitrido and µ-oxo complexes were tested for biological activity.
None of the complexes were found to be cytotoxic by the MTT assay. Three compounds,
3.1, 4.1 and 4.2, showed mitochondrial calcium uptake inhibition. Compound 4.1 had
the highest cellular uptake in both HeLa and HEK293 cells and showed calcium uptake
inhibition in unpermeabilized HEK293 cells. Compound 4.1 interacts with the MCU through
5Thanks to Santhanam Shanmughapriya and Neeharika Nemani in the group of Madesh Muniswamy for
this data
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a conserved serine and aspartate; mutations of these residues greatly reduced the complex’s
inhibitory ability.
Different axial ligand substitution kinetics may play an important role in the relative
activity of these species. It is reported, for example, that the formate ligands of Ru360
aquate at a faster rate than the chloride analogue.233 Additionally, the complex chemical
environment of biological media contains a range of potential ligands that may affect the
formation of the true active species. Using EPR, we showed that compound 3.1 is unstable
over 24 hr in complete cell growth media, forming unknown EPR-active species. Considering
the difference in activities between Ru360, which bears axial formate groups, and compound
3.1, which bears axial water ligands, it appears that the nature of the axial ligands plays a
large role in the inhibitory activity. The difference in inhibition constants is remarkable – 3.1
is 10× more effective. The difference between compound 4.1 (ammine equatorial ligands)
and 4.2 (en equatorial ligands) is also striking – 4.1 is 36× more effective than 4.2. Further
modifications of the axial and equatorial ligands may lead to more effective MCU inhibitors
by optimizing ligand substitution kinetics.
The difference in MCU-inhibitory activity of the complexes supports a two-part hypoth-
esis for the mechanism of inhibition. First, the serine is tightly binding through the axial
position of the complexes. Mutation of this serine greatly attenuates the MCU-inhibitory
ability of these complexes. This could be either covalent, through a nucleophilic attack of the
serine hydroxy to the electrophilic ruthenium to displace the axial ligand, or simply through
a hydrogen-bonding interaction. As a formate group is both a poorer leaving group, and is
less effective in hydrogen bonding in comparison to a water, the obtained data cannot differ-
entiate between these two options. Second, the ability of the equatorial ligands to hydrogen
bond with the aspartate residues mediates the inhibition. Compounds 4.1 and 4.2 only
differ in their equatorial ligands. The ethylenediamine ligands of 4.2 cannot form hydrogen
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bonds as effectively as 4.1, and therefore is a less effective inhibitor. Compounds 4.3-4.5
have very poor hydrogen bonding capabilities, both in the axial and equatorial positions and
no calcium uptake inhibition is observed.
A docking study looking at the interaction between Ru360 and the MCU corroborates the
importance of the hydrogen bonding network with the equatorial ligands.186 Structure activ-
ity relationship studies and docking studies with mitoxantrone indicate that long sidechain
moieties with multiple hydrogen binding sides are necessary for inhibition.185 Additional
studies will be needed to consider the exact role of the axial vs equitorial ligands. Moreover,
molecular biology studies to determine the method of cellular uptake and off-target protein
interactions, and success in protection in ischemic-reperfusion injury models will elucidate
the efficacy of these compounds for potential therapeutics.
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APPENDIX A
EXPERIMENTAL DETAILS FOR [(OH2)(NH3)4RU(µ–O)RU(NH3)4(OH2)]
5+
A.1 General methods and materials
Ruthenium trichloride hydrate (RuCl3 · n H2O, 40% Ru) was purchased from Pressure
Chemical and used as received. Ru360 was purchased from EMD Millipore Calbiochem (Lot
# 2660892). Solvents, including concentrated HCl and NH3, were ACS reagent grade and
used as received. Purifications employed Dowex 50WX2 200-400 mesh (H+ form) strongly
acidic cation exchange resin, which was purchased from Alfa Aesar. Prior to chromato-
graphic separation, the resin was treated 35 column volumes of 0.1 M HCl. [Ru(NH3)5Cl]Cl2
and potassium µ-oxo-bis[pentachlororuthenate(IV)] were prepared via previously published
procedures.279,370
A.2 Physical measurements
FTIR spectra were acquired on a Bruker Hyprion FTIR, with ZnSe ATR attachment
for solid powders. Elemental analyses were performed by Atlantic Microlab, Inc. (Norcross,
GA). Electrochemical measurements were carried out using a Pine Instruments WaveNow
potentiostat. A three-electrode cell comprising a glassy carbon working electrode, a platinum
counter electrode, and a Ag/AgCl reference electrode was used. Samples were dissolved to a
final concentration of approximately 2-5 mM in 0.10 M pH 7.6 ammonium formate and were
degassed with nitrogen for at least 15 minutes prior to analysis. UV-visible absorbance spec-
tra were acquired with an Agilent Cary 8454 spectrophotometer. Near-IR absorbance spectra
were collected on a Shimadzu 3600 UV-Vis/NIR spectrophotometer. Samples for electron
paramagnetic resonance (EPR) spectroscopy were prepared in 20% glycerol/water solution
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and frozen in liquid nitrogen in 4 mm thin wall quartz tubes. EPR spectra were recorded at
a microwave frequency of 9.4 GHz on a BRUKER ELEXYS-II E500 spectrometer equipped
with a liquid helium cryostat ESR10 in the ACERT center (National Biomedical Center
for Advanced ESR Technology) at Cornell University. Concentrations of the Ru-containing
solutions were determined by graphite furnace atomic absorption spectroscopy (GFAAS). A
Perkin-Elmer PinAAcle 900Z GFAAS was used with end-capped graphite tubes, and certified
calibration standards in the range of 25-100 µg/L were used to create suitable calibration
curves. All solutions used in cellular studies were made in MilliQ 18 M· cm water. X-ray
powder diffraction patterns (Figure A.1) were recorded on a Scintag Powder X-Ray Diffrac-
tometer in 2θ medium resolution Brag Brentano geometry employing Cu Kα line focused
radiation at 40 kV, 44 mA power and equipped with a Ge crystal detector fitted with a 1.0
mm radiation entrance slit. Samples were mounted on zero background sample holders by
dropping powders from a wide-blade spatula and then leveling the sample surface with the
back of the spatula. No sample grinding was used. Samples were observed using a continuous
2θ scan from 1.5 – 50 °(Omega = 1.0 °). Orca (version 3.03) was used for all computations.
DFT analysis used the BP86 functional and def2-TZVP(-f) basis set for geometry optimiza-
tion. The ZORA correction was applied to account for relativist effects due to the presence
of heavy atoms and the RI approximation was also applied for Coulomb integral approxima-
tions. TDDFT utilized the PBE0 functional with the RICOSX approximation. A solvent
(water) correction was applied to all calculations using the COSMO function.
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Figure A.1: X-ray powder diffraction pattern of K4[Ru2OCl10]. Theoretical spectrum calcu-
lated from the crystal structure data using Mercury software (v. 3.8, Cambridge Crystallo-
graphic Data Centre).
A.3 Synthetic methods for [(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]
5+
(3.1)
A.3.1 Method 1
This method was based on a previous literature protocol.233 Ruthenium trichloride hy-
drate (250 mg, 1.11 mmol for the monohydrate) was refluxed in 1.5 mL 6 M HCl and 1 mL
ethanol for 1 hr to reduce Ru(IV) and nitrosyl-containing impurities. A 250 µL volume of
d=0.88 NH4OH was added, and a dark red-brown solid precipitated immediately. This mix-
ture was centrifuged while still warm. The supernatant was discarded, and 20 mL of d=0.88
NH4OH was added to the remaining solid. The reaction was heated at 90 °C for 5 min and
then allowed to stir at 40 °C overnight. The crude product was precipitated with approxi-
mately 60 mL ethanol, and the resulting suspension was chilled at 4 °C. The compound was
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isolated by centrifugation, dissolved in ∼20 mL 0.1 M HCl, and loaded immediately onto a
DOWEX 50WX2 cation exchange column (5 g resin for 1/2 of the crude product, 10 mm
diameter column) pre-equilibrated with 0.1 M HCl. The desired complex was eluted using
1-3 M HCl gradient, with the product beginning to move at 2 M and completely eluting at
3 M. A yellow byproduct, [Ru(NH3)5Cl]Cl2, elutes at 1.5 M HCl, and ruthenium red and
related impurities elute at as the HCl concentration is increased to 4 M. Fractions containing
only the 360 and 600 nm absorbance bands were pooled and evaporated to dryness to obtain
the compound as a green-brown solid 3.1. Yield: 18 mg (2.7%). Elemental analysis: calcd %
for [(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH2)]Cl5·1.5H2O: C 0.00, H 5.25, N 18.84, Cl 29.81%;
found: C 0.00, H 4.95, N 18.39, Cl 29.96.
A.3.2 Method 2
[Ru(NH3)5Cl]Cl2 (100 mg, 0.34 mmol) was dissolved in 50 mL 1 M NH4OH, heated at
60 °C for 6 hr in a loosely capped 200 mL round-bottom flask, and then left to stir at
room temperature for 3 days. The pH of the resulting green solution was adjusted with
concentrated HCl to <7, resulting in a color change of the solution from green to brown,
and then loaded immediately on a DOWEX 50WX2 cation exchange column (5 g resin, 10
mm diameter column) pre-equilibrated with 0.1 M HCl. The compound was isolated from
this column as described in method 1. Yield: 20 mg (9.8%).
A.3.3 Method 3
K4[Ru2OCl10] (50 mg, 0.11 mmol) was suspended in 50 mL d=0.88 NH4OH and heated
at 50 °C in a loosely capped 200 mL round-bottom flask for 30 min. The reaction mixture
was filtered while hot through a pad of Celite. To the dark green filtrate was added 150
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mL of ethanol, and the resulting suspension was cooled at 4 °C for 1-2 hr. The green solid
was isolated by centrifugation, dissolved in 0.1 M HCl (∼20 mL), and loaded on a DOWEX
50WX2 cation exchange column (5 g resin, 10 mm diameter) pre-equilibrated with 0.1 M
HCl. The compound was eluted as described above. It should also be noted that a purple-
pink impurity sometimes eluted at the tail end of the fraction containing the compound, so
additional care must was to avoid contamination of the desired product. Yield: 5 mg (7.6%).
A.4 X-ray crystallography
Red prisms of [(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH)]
4+ were grown by the vapor dif-
fusion of ethanol into an aqueous solution of 3.1. Crystals of K4[Ru2OCl10] were grown
by the slow evaporation of a 2.5 M HCl solution at elevated temperatures. Crystals
of [Ru(NH3)5Cl]Cl2 were obtained directly from the cation exchange purification of 3.1
via slow evaporation of the fractions containing 2 M HCl. X-ray diffraction data for
[(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH)]
4+, [Ru(NH3)5Cl]Cl2 and K4[Ru2OCl10] were col-
lected on a Bruker APEX 2 CCD Kappa diffractometer (Mo Kα, λ = 0.71073 A˚) at 223 K.
The structures were solved through intrinsic phasing using SHELXT371 and refined against
F2 on all data by full-matrix least squares with SHELXL372 following established refine-
ment strategies.373 All non-hydrogen atoms were refined anisotropically. Hydrogen atoms
of NH3 ligands were included in the model at geometrically calculated positions and re-
fined using a riding model, allowing the torsion angle to refine (HFIX 137). The OH
hydrogen atom of [(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH)]
4+ was located on the difference
Fourier map, and refined semi-freely, constraining the O–H distance to 0.83 A˚ and the ther-
mal ellipsoid of the H atom to be 1.5 times that of the oxygen atom. In the structure
of [(OH2)(NH3)4Ru(µ–O)Ru(NH3)4(OH)]
4+, heavily disordered electron density, centered
around a crystallographic inversion center, could not be satisfactorily refined as discrete sol-
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vent molecules. This residual electron density was modeled using the SQUEEZE function in
PLATON.374 Residual electron density in a solvent-accessible void of 36.8 A˚3 accounts for
approximately 11 e-. We hypothesize that this density corresponds to a disordered water
molecule (10 e-). Details of the data quality and a summary of the residual values of all the
refinements are listed in Tables A.1, A.2, A.3, and 3.1.
Table A.1: Selected distances and angles for [Ru(NH3)5Cl]Cl2. Labels are as shown in Figure
3.3a. Numbers in parentheses are the estimated standard deviation in the last significant
figures.
Interatomic Distances [A˚] Interatomic Angles [°]
N1–Ru 2.082(3) N2-Ru-Cl1 90.69(8)
N2–Ru 2.111(3) N4-Ru-Cl1 89.71(5)
N3–Ru 2.107(3) N1-Ru-N2 89.40(12)
N4–Ru 2.100(2) N1-Ru-N3 89.33(12)
Cl1–Ru 2.3494(8) N1-Ru-N4 90.29(5)
N2-Ru-N4 89.94(5)
N3-Ru-N4 90.07(5)
Table A.2: Selected bond distances and angles for K4[Ru2OCl10]. Labels are as shown
in Figure 3.3b. Numbers in parentheses are the estimated standard deviation in the last
significant figures.
Interatomic Distances [A˚] Interatomic Angles [°]
Cl1–Ru1 2.3185(16) O1-Ru1-Cl1 180.00
Ru1–O1 1.8066(6) Cl2-Ru1-Cl1 87.12(2)
Ru1–Cl2 2.3672(8) Cl2-Ru1-O1 92.88(2)
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Table A.3: Selected bond distances and angles for Ru360 analog. Labels are as shown
in Figure 3.5. Numbers in parentheses are the estimated standard deviation in the last
significant figures.
Interatomic Distances [A˚] Interatomic Angles [°]
O2–Ru 1.8218(2) Ru-O2-Ru 180.000(12)
Ru–O1 2.039(2) O1-Ru-O2 178.45(7)
N3–Ru 2.110(3) N1-Ru-N2 91.33(10)
N4–Ru 2.108(2) N1-Ru-N4 88.80(10)
N1–Ru 2.105(3) N2-Ru-N3 89.56(10)
N2–Ru 2.102(2) N3-Ru-N4 90.18(10)
N1-Ru-O1 88.32(10)
N1-Ru-O2 90.66(7)
N2-Ru-O1 89.91(9)
N2-Ru-O2 91.28(6)
O2-Ru-N4 92.52(6)
O1-Ru-N4 86.30(9)
N2-Ru-N4 176.20(9)
O2-Ru-N3 91.43(7)
O1-Ru-N3 89.58(10)
N1-Ru-N3 177.72(10)
A.5 Aqueous stability
Stock solutions of 3.1 for use in biological studies were made in MilliQ 18 MΩ·cm water
to final concentrations ranging from 1-5 mM. Aliquots were stored at –20 °C in between
use for short term stability. The stability of the stock solutions to freeze-thaw cycles was
determined by analyzing the UV-Vis spectrum of a solution before and after five freeze-
thaw cycles, over the course of five days. UV-vis spectroscopy revealed that the compound
remained approximately 90% intact after being subjected to these conditions as well. To
assess long term stability of the complex, the stock solution was frozen at –80 °C for three
months. The UV-Vis spectrum was measured after this time, and the sample was determined
to be greater than 90% pure based on the intensities of the absorbance bands.
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Solutions of complex 3.1 (1 mM) were dissolved in 1× PBS with 5 mol equivalent of
glutathione and incubated at 37 °C. Samples were taken at t = 0 and t = 24 hr to assess
stability. 20% glycerol was added to the samples and were analyzed by EPR at 20 K.
Solutions of complex 3.1 (0.5 mM) in DMEM containing 10% FBS (fetal bovine serum)
were incubated at 37 °C for 24 hr. Samples were taken at t = 0 and t = 24 hr to access
stability. 20% glycerol was added to the samples and were analyzed by EPR at 20 K.
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APPENDIX B
EXPERIMENTAL DETAILS FOR SUBSTITUTED DIRUTHENIUM
µ-NITRIDO SYSTEMS
B.1 General methods and materials
Ruthenium trichloride hydrate (RuCl3 · n H2O, 40% Ru) was purchased from Pressure
Chemical and used as received. Ru360 was purchased from EMD Millipore Calbiochem (Lot
# 2660892). Solvents, including concentrated HCl and NH3, were ACS reagent grade and
used as received. Potassium chloride, stannous chloride and potassium nitrite were purchased
from Macron Fine Chemicals, Fisher Scientific and Alfa Aesar, respectively, and used as re-
ceived. K2[RuCl5NO] and K3[Ru2NCl8(H2O)2] were prepared based on previously published
procedures.306,307 2,2’-bipyridine (bpy) was obtained from Alfa Aesar. 4,4’-dimethoxy-2,2’-
bipyridine (dmobpy) and 4,4’-dimethyl-2,2’-bipyridine (dmbpy) were purchased from Sigma-
Aldrich and used as received.
B.2 Physical measurements
FTIR spectra were acquired on a Bruker Hyprion FTIR, with ZnSe ATR attachment
for solid powders. Elemental analyses were performed by Atlantic Microlab, Inc. (Norcross,
GA). UV-visible absorbance spectra were acquired with an Agilent Cary 8454 spectropho-
tometer. Conductance measurements were performed using a Sper Scientific model 860032
conductivity meter. Extinction coefficients of 4.1 and 4.2 were taken in pH 7.4 1×PBS and
4.3, 4.4 and 4.5 were taken in DMSO. 1H NMR were acquired on a 400 MHz INOVA spec-
trometer or a 500 MHz Bruker AV 3HD spectrometer equipped with a broadband Prodigy
cryoprobe. 13C{1H} NMR spectra were acquired on a 500 MHz Bruker AV 3HD spectrometer
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equipped with a broadband Prodigy cryoprobe. A Pine Instruments WaveNow potentiostat
and a three electrode cell including a glassy carbon working electrode, a platinum counter
electrode, and a silver reference electrode were used to acquire cyclic voltammograms at a
scan rate of 100 mV/s. Compounds were dissolved in a 0.10 M solution of [Bu4N][PF6] in
DMF. Nitrogen gas was bubbled into the solution to deoxygenate the cell before analysis.
An internal standard, ferrocene (0.45 V vs SCE), was used to reference the potentials.375,376
Orca (version 3.03) was used for all computations. DFT analysis used the BP86 functional
and def2-TZVP(-f) basis set for geometry optimization and vibrational frequency calcula-
tions. The ZORA correction was applied to account for relativist effects due to the presence
of heavy atoms and the RI approximation was also applied for Coulomb integral approxima-
tions. TDDFT utilized the PBE0 functional with the RICOSX approximation. A solvent
(water or DMSO) correction was applied using the COSMO function.
B.3 Synthetic methods
B.3.1 Synthesis of K2[Ru(Cl)5NO] (4.SM1)
RuCl3 · n H2O (1g, 4.82 mmol (monohydrate)) and KNO2 (1.3 g, 15.3 mmol) were com-
bined and refluxed in 20 mL of 0.5 M HCl for one hour. To the red solution KCl (1.13 g, 15.2
mmol) and 3 mL 11.6 M HCl were added and reflux was continued for 3 hrs. The resulting
magenta solution was heated at 106 °C under air stream to remove solvent until dark purple
crystals started to form (∼5 mL solvent remaining). The crystals were filtered and washed
with copious amounts of 50% ethanol in water, ethanol, ether and then air dried. Yield: 750
mg, 43% yield.
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B.3.2 Synthesis of K3[Ru2NCl8(H2O)2] (4.SM2)
SnCl2 (1.27 g, 6.69 mmol) was dissolved in 2.5 mL of 6 M HCl and added to 4.SM1 (1 g,
2.58 mmol) in 15 mL H2O and refluxed for 1 hour to form a red-brown solution. The solvent
was evaporated at 104 °C under an air stream until red-brown crystals crashed out (2-5 mL
left). The crystals were filtered and washed with 50% ethanol in water, ethanol, ether and
air dried. Yield: 325 mg, 38% yield.
B.3.3 Synthesis of [Ru2N(NH3)8(H2O)2]Cl5 (4.1)
182 mg (0.278 mmol) of K3[Ru2NCl8(H2O)2] was dissolved in 50 mL of d=0.88 NH4OH
293
and heated in a loosely stoppered flask at 75 °C for 6 hours to yield a clear bright orange
solution with a fine grey-brown precipitate. The precipitate was assumed to be residual SnO2
left over from the formation of 4.SM2. The reaction was cooled, filtered and the filtrate
concentrated to dryness by rotory evaporation. The crude solid was dissolved in 25 mL of
hot water, precipitated via the addition of 5 mL concentrated HCl, cooled overnight, filtered
and washed with 6 M HCl, ethanol and diethyl ether to yield crude orange microcrystalline
solid (83 mg). Pure complex was recrystallized by acetone diffusion into aqueous solutions
over 1-2 weeks. Yield after filtering and washing with ethanol and diethyl ether: 39 mg, 26%
yield. 1H NMR (400 MHz, DMSO-d6): δ 4.14 (s, 24H). IR (ATR, cm
−1): 1047(s). Elemental
analysis: calcd % for Ru2N(NH3)8(Cl)2Cl3 · 1.5 H2O: C 0.77, H 4.99, N 22.38, Cl 31.46%;
found: C 0.73, H 4.42, N 21.84, Cl 30.29%.
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B.3.4 Synthesis of [Ru2N(en)4(Cl)2]Cl3 (4.2)
100 mg (0.153 mmol) of K3[Ru2NCl8(H2O)2] was suspended in 1 mL H2O and warmed.
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1 mL of ethylenediamine (en) was combined with 1 mL H2O and stirred on a 90 °C oil bath.
After about 5 minutes, the 4.SM2 solution was added to the hot ethylenediamine solution
and then heated for 1 hour. After cooling and filtering, 30 mL of ethanol was added and the
reaction cooled overnight. The crude product was isolated by centrifugation and dissolved in
4-6 mL water. The addition of 1-2 mL of concentrated HCl and chilling overnight precipitates
pure orange microcrystals. Yield after filtering and washing with ethanol and diethyl ether:
28 mg, 28% yield. 1H NMR (400 MHz, D2O vs dioxane): δ 5.49 (bs, 8H), 5.33 (bs, 8H), 3.28
(m, 8 H), 2.85 (m, 8H). 13C{1H} NMR (125 MHz, D2O): 46.44. IR (ATR, cm-1): 1055(s).
Elemental analysis: calcd% for Ru2N(C2N2H8)4Cl5·2.5H2O: C 14.15, H 5.49, N 18.57%;
found: C 14.20, H 5.26, N 18.19%.
B.3.5 Synthesis of [Ru2N(bpy)2Cl5(DMF)] (4.3)
Suspensions of K3[Ru2NCl8(H2O)2] (300 mg, 0.459 mmol) and 2,2’-bipyridine (358 mg,
2.295 mmol) in 3 mL of water and 7 mL of acetone, respectively, were warmed at 45 °C
for 10 min to ensure full dissolution of these compounds. Once dissolved, the resulting
solutions were mixed and heated under reflux for 8 h. The resulting red-brown crude solid
was isolated by filtration and washed with acetone and diethyl ether. This crude solid (180
mg) was suspended in DMF (12 mL), sonicated for 15 min, stirred at rt for 30 min, and
then filtered. The vapor diffusion of methanol into the resulting dark red filtrate afforded
red crystals of the desired compound after a week. Yield: 60 mg, 16% yield. 1H NMR (600
MHz, DMSO-d6): 9.98 (dd, J = 5.6 and 1.5 Hz, 1H), 9.61 (dd, J = 5.7 and 1.5Hz, 2H), 8.85
(dd, J = 5.6 and 1.7 Hz, 1H), 8.71 (d, J = 8.0 Hz, 2H), 8.61 (d, J = 8.1 Hz, 1H), 8.53 (d, J
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= 8.2 Hz, 1H), 8.39 (td, J = 7.8 and 1.5 Hz, 2H), 8.20 (td, J = 7.9 and 1.5 Hz, 1H), 8.16
(td, J = 7.8 and 1.7 Hz, 1H), 7.84 (ddd, J = 7.8, 5.6, and 1.3 Hz, 2H), 7.75 (ddd, J = 7.8,
5.6, and 1.3 Hz, 1H), 7.61 (ddd, J = 7.8, 5.5 and 1.0 Hz, 1H). 13C{1H} NMR (125 MHz,
DMSO-d6): 158.18, 155.45, 154.74, 153.33, 152.71, 149.20, 140.94, 140.14, 139.38, 126.09,
126.02, 125.76, 123.56, 123.27, 122.55. IR (ATR, cm−1): 1030(s) and 1074(w). Anal. calcd
for 4.5, C23H23Cl5N6ORu2: C, 35.47; H, 2.98; N, 10.79%. Found: C, 35.27; H, 3.50; N,
10.53%.
B.3.6 Synthesis of [Ru2N(dmbpy)2Cl5(DMF)] (4.4)
Suspensions of K3[Ru2NCl8(H2O)2] (300 mg, 0.459 mmol) and 4,4’-dimethyl-2,2’-
bipyridine (338 mg, 1.836 mmol) in 3 mL of water and 7 mL of acetone, respectively, were
warmed at 45 °C for 10 min. The resulting acetone suspension and aqueous solution were
mixed and heated under reflux for 6 h. The resulting red-brown crude solid was isolated
by filtration and washed with chloroform and diethyl ether. To further purify the complex
from excess dmbpy ligand, the crude solid was suspended in 10 mL of chloroform and heated
under reflux for 2 h, and then isolated again by filtration while still warm. As a final means
of purification, the solid (120 mg) was suspended in 6 mL of DMF, sonicated for 30 min,
stirred at rt for 1 h, and then filtered. The dark red filtrate, which contains pure product,
was subjected to vapor diffusion with methanol. Over the course of the week, red crystals
of the desired product were obtained. Yield: 14 mg, 3.5% yield. Note: additional batches
of pure product can be obtained by repeating the sonication procedure with the crude solid.
The product is only sparingly soluble in DMF, so the isolation of more compound requires
repeated extractions in this solvent. 1H NMR (600 MHz, DMSO-d6): 9.77 (d, J = 5.8 Hz,
1H), 9.40 (d, J = 5.6 Hz, 2H), 8.67 (d, J = 5.7 Hz, 1H), 8.55 (s, 2H), 8.45 (s, 1H), 8.37 (s,
1H), 7.65 (d, J = 6.0 Hz, 2H), 7.56 (d, J = 5.9Hz, 1H), 7.42 (d, J = 5.9 Hz, 1H), 2.60(s,
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2H), 2.59 (s, 1H), 2.45 (s, 1H). 13C{1H} NMR (125 MHz, DMSO-d6): 157.67, 154.67, 154.24,
153.10, 152.48, 151.84, 151.76, 150.99, 148.45, 126.70, 126.38, 126.18, 123.97, 123.66, 122.94,
21.00, 20.80, 20.43. IR (ATR, cm−1): 1020(w), 1032(s), 1065(s), and 1084(w). Anal. calcd
for 4.4, C27H35Cl5N6O3Ru2: C, 37.23; H, 4.05; N, 9.65%. Found: C, 37.27; H, 4.17; N 9.60%.
B.3.7 Synthesis of [Ru2N(dmobpy)2Cl5(DMF)](4.5).
Suspensions of K3[Ru2NCl8(H2O)2] (300 mg, 0.459 mmol) and 4,4’-dimethoxy-2,2’-
bipyridine (397 mg, 1.836 mmol) in 3 mL of water and 7 mL of acetone, respectively, were
warmed at 45 °C for 10 min. The resulting acetone suspension and aqueous solution were
mixed and heated under reflux for 6 h. The resulting red-brown crude solid was isolated by
filtration and washed with chloroform and diethyl ether. To remove excess dmobpy ligand,
the crude solid was suspended in 10 mL of chloroform and heated under reflux for 2 h, and
then isolated again by filtration. For further purification, the solid was then suspended in
10 mL of 6:4 acetone:water, heated at reflux for 4 h, and then filtered. This crude solid
(120 mg) was suspended in 12 mL of DMF, sonicated for 30 min, stirred at rt for 1 h, and
then filtered. The dark red filtrate, which contains pure product, was subjected to vapor
diffusion with methanol to afford the product as red crystals. Yield: 22 mg, 5.3% yield.
Note: as described above, more pure product can be obtained by sequential extractions of
the remaining crude solid with DMF as described. 1H NMR (600 MHz, DMSO-d6): 9.71 (d,
J = 6.6 Hz, 1H), 9.35 (d, J = 6.7 Hz, 2H), 8.66 (d, J = 6.5 Hz, 1H), 8.29 (d, J = 2.8 Hz, 2H),
8.22 (d, J = 2.8 Hz, 1H), 8.10 (d, J = 2.5 Hz, 1H), 7.42 (dd, J = 6.7 and 2.7 Hz, 2H), 7.34
(dd, J = 6.7 and 2.7 Hz, 1H), 7.21 (dd, J = 6.6 and 2.5 Hz, 1H), 4.08 (s, 2H), 4.07 (s, 1H),
3.97 (s, 1H). 13C{1H} NMR (125 MHz, DMSO-d6): 168.29, 167.90, 167.70, 159.35, 156.27,
155. 67, 155.00, 153.61, 150.21, 111.65, 111.19, 110.80, 109.83, 108.90, 57.00, 56.87, 56.71.
IR (ATR, cm−1): 1015(s), 1030(vs), 1049(vs), 1065(s), and 1074(vw). Anal. calcd for 4.5,
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C27H31Cl5N6O5Ru2: C, 36.07; H, 3.48; N, 9.35%. Found: C, 35.80; H, 3.64; N, 9.15%.
B.4 X-ray crystallography
Low-temperature X-ray diffraction data for compound 4.2 were collected on a Rigaku
XtaLAB Synergy diffractometer coupled to a Rigaku Hypix detector with Cu Kα radia-
tion (λ = 1.54184 A˚), from a PhotonJet micro-focus X-ray source at 100 K. The diffraction
images were processed and scaled using the CrysAlisPro software.377 Low-temperature X-
ray diffraction data for 4.1 and 4.SM2 were collected on a Bruker APEX 2 CCD Kappa
diffractometer (Mo Kα, λ = 0.71073 A˚) at 223 K. The diffraction images were processed
and scaled using the APEX2 software.378 The structures were solved through intrinsic phas-
ing using SHELXT371 and refined against F2 on all data by full-matrix least squares with
SHELXL372 following established refinement strategies.373 All non-hydrogen atoms were re-
fined anisotropically. All hydrogen atoms bound to carbon were included in the model at
geometrically calculated positions and refined using a riding model. Hydrogen atoms bound
to nitrogen in 4.2 and oxygen in 4.SM2 were located in the difference Fourier synthesis and
subsequently refined semi-freely with the help of distance restraints. The isotropic displace-
ment parameters of all hydrogen atoms were fixed to 1.2 times the Ueq value of the atoms
they are linked to (1.5 times for methyl groups). The unit cell of 4.1 contained disordered
solvent molecules, which have been treated as diffuse contributions to the overall scattering
without specific atom positions using the solvent mask routine in Olex2.379 The unit cell of
4.3 contained 3 methanol molecules and the unit cell of 4.5 contained three DMF molecules,
which have been treated as diffuse contributions to the overall scattering without specific
atom positions using the solvent mask routine in Olex2. Details of the data quality and a
summary of the residual values of the refinements are listed in Tables B.2, B.3, B.4, B.1,
B.5, B.6, 4.1, and 4.2.
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Table B.1: Unit Cell Parameters for K2[RuCl5NO].
Crystal Data
Morphology Block
Crystal System Orthorhombic
Volume/ A˚3 960
a/A˚ 6.91
b/A˚ 10.42
c/A˚ 13.35
α/° 90
β/° 90
γ° 90
Table B.2: Relevant distances and angles for K3[Ru2NCl8(H2O)2]. Labels are as shown
in Figure 4.2a. Numbers in parentheses are the estimated standard deviation in the last
significant figures.
Interatomic Distances [A˚] Interatomic Angles [°]
Cl1–Ru 2.3858(4) N1-Ru-O1 179.99(5)
O1–Ru 2.1790(17) Ru-N-Ru 180.0
Cl2–Ru 2.3699(4) Cl2-Ru-Cl1 171.595(16)
N1–Ru 1.7251(2) Cl1-Ru-O1 84.95(4)
Cl2-Ru-O1 86.65(4)
Cl1-Ru-N1 95.038(12)
Cl2-Ru-N1 93.359(12)
Table B.3: Selected bond distances and angles for [(OH)(OH2)(NH3)8Ru2(µ–N)](SiF6)2.
Labels are as shown in Figure 4.4a. Numbers in parentheses are the estimated standard
deviation in the last significant figures.
Interatomic Distances [A˚] Interatomic Angles [°]
N1–Ru 1.7374(3) Ru-N1-Ru 180.0
Ru–O1 2.082(2) O1-Ru-N1 179.52(6)
N2–Ru 2.101(3) N1-Ru-N2 93.67(8)
N3–Ru 2.102(2) N1-Ru-N3 94.05(6)
N4–Ru 2.108(2) N1-Ru-N4 96.70(7)
N3-Ru-N4 89.36(6)
N2-Ru-N3 89.90(6)
N2-Ru-O1 86.82(10)
N3-Ru-O1 85.94(6)
N4-Ru-O1 82.82(10)
N2-Ru-N4 169.64(10)
113
Table B.4: Selected bond distances and angles for [Cl(en)2Ru(µ–N)Ru(en)2Cl]Cl3. Labels
are as shown in Figure 4.4b. Numbers in parentheses are the estimated standard deviation
in the last significant figures.
Interatomic Distances [A˚] Interatomic Angles [°]
N1–Ru 1.7592(3) Ru-N1-Ru 176.3(2)
N2–Ru 2.105(3) N1-Ru-Cl1 177.59(10)
N3–Ru 2.104(3) N1-Ru-N2 95.46(10)
N4–Ru 2.106(3) N1-Ru-N3 96.21(15)
N5–Ru 2.108(3) N1-Ru-N4 95.12(9)
Cl1–Ru 2.4550(8) N1-Ru-N5 94.58(14)
N2-Ru-Cl1 84.03(8)
N2-Ru-N4 169.26(11)
N2-Ru-N5 99.05(10)
N3-Ru-Cl1 86.05(8)
N3-Ru-N2 81.58(10)
N3-Ru-N4 95.49(10)
N3-Ru-N4 169.09(11)
N4-Ru-Cl1 85.47(8)
N4-Ru-N4 81.87(10)
N4-Ru-Cl1 83.19(8)
Table B.5: Selected bond distances and angles for [Ru2N(bpy)2Cl5(DMF)]. Labels are as
shown in Figure 4.6a. Numbers in parentheses are the estimated standard deviation in the
last significant figures.
Interatomic Distances [A˚] Interatomic Angles [°]
N3–Ru1 2.0548(14) Ru2-N1-Ru1 173.10(9)
N4–Ru2 2.0532(14)
N5–Ru2 2.0607(15)
N2–Ru1 2.1626(14)
Ru1–N1 1.7351(14)
Ru2–N1 1.7256(13)
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Table B.6: Selected bond distances and angles for [Ru2N(dmobpy)2Cl5(DMF)]. Labels are
as shown in Figure 4.6b. Numbers in parentheses are the estimated standard deviation in
the last significant figures.
Interatomic Distances [A˚] Interatomic Angles [°]
N3–Ru1 2.0646(18) Ru2-N1-Ru1 177.22(11)
N4–Ru2 2.0567(18)
N5–Ru2 2.0596(19)
N2–Ru1 2.1546(19)
Ru1–N1 1.7375(18)
Ru2–N1 1.7219(18)
B.5 Aqueous kinetics
Stock solutions of 4.1 and 4.2 were made in MilliQ 18 M·cm water to final concentrations
ranging from 1 to 3 mM. Solutions were used immediately. Various concentrations of of
HClO4 were used to probe pH dependence between pH 1 and 3.5.
B.6 Conductivity
Solutions of 4.1 and 4.2 were made in MilliQ 18 M·cm water to final concentrations
ranging from 0.45 to 0.5 mM.
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B.7 NMR spectra
Figure B.1: 1H NMR of Compound 4.2 in D2O.
Figure B.2: 13C{1H} NMR of Compound 4.2 in D2O.
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Figure B.3: 13C{1H}/1H HSQC NMR of Compound 4.2 in D2O. The cross peaks show the
smaller, inner peaks at 2.96 and 2.76 ppm in the proton NMR are associated with the small
peak at 46.32 ppm in the 13C NMR.
Figure B.4: 1H NMR of Compound 4.3 in DMSO-d6.
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Figure B.5: 13C{1H} NMR of Compound 4.3 in DMSO-d6.
Figure B.6: 1H NMR of Compound 4.4 in DMSO-d6.
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Figure B.7: 13C{1H} NMR of Compound 4.4 in DMSO-d6.
Figure B.8: 1H NMR of Compound 4.5 in DMSO-d6.
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Figure B.9: 13C{1H} NMR of Compound 4.5 in DMSO-d6.
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APPENDIX C
EXPERIMENTAL DETAILS FOR BIOLOGICAL ASSAYS
C.1 Cell culture
HeLa (human cervical cancer) cells were grown as adherent monolayers in growth medium
consisting of Dulbeccos Modified Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS). The cultures were grown in 100 cm2 petri dishes in an incubator at 37
°C with a humidified atmosphere composed of 5% CO2. Cells were tested for mycoplasma
contamination at least monthly with the PlasmoTestTM Mycoplasma Detection Kit (Invivo-
Gen).
C.2 Cell viability assays
Stock solutions of the complexes were prepared in H2O ([Cl10Ru2(µ–O)], trans-
[(NH3)4Cl2Ru]
+, 4.SM2, 3.1, 4.1, 4.2) or DMSO (4.3, 4.4, 4.5) at concentrations be-
tween 2-3 mM. Cells were seeded in a 96-well plate at a density of about 2000 cells/well
for HeLa cells and in a 6-well plate at a density of about 4000 cells/well for HEK293 cells.
For Hela cells, after 24 hr, the growth medium was removed and replaced with 200 µL of
growth medium containing varied concentrations of the complexes of interest. After an ad-
ditional 72 hr incubation, the medium was removed and replaced with 200 µL of 5 mg/mL
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), diluted in serum-free
medium. After 46 hr, the MTT was removed, and the resulting purple formazan crystals
were dissolved in 200 µL DMSO containing 17% 0.1 M glycine and 0.1 M NaCl at pH 10.5.
The absorbance at 570 nm in each well was determined using a BioTek Synergy HT plate
reader. Six replicates per concentration level and at least three independent experiments
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were completed for each compound. For HEK293 cells, after 24 hr the cells were dosed at
25 µM without removing the growth media. After an additional 72 hr incubation 400 µL
of 5 mg/mL MTT was added. After 3-5 hr, the cells and MTT were removed, transferred
to a 5 mL round-bottom tube and centrifuged for 10 minutes at 1000× (5310g). The su-
pernatant was removed and the resulting purple formazan crystals were dissolved in 2 mL
DMSO containing 17% 0.1 M glycine and 0.1 M NaCl at pH 10.5. Each sample was plated
onto a 96-well place and the absorbance at 570 nm in each well was determined using a
BioTek Synergy HT plate reader. Three replicates were completed for each compound.
C.3 Mitochondrial calcium uptake in permeabilized HeLa cells
HeLa (human cervical cancer) cells were amplified in 500 cm2 petri dishes. Growth
media was removed, and HeLa cells at 80-100% confluency were washed once with 1× PBS,
incubated with 1 mM EDTA in 1× PBS for 10 minutes, and gently agitated to detach cells
from the surface. Cells were centrifuged for 10 minutes at 1000× (5310g) and re-suspended
in a pH 7.4 buffered glucose-containing salt solution (BGSS: 110 mM KCl, 1mM KH2PO4,
1mM MgCl2, 20 mM HEPES, 5 mM sodium succinate, 30 µM EGTA, 1 mg/mL glucose)
with a final cell density of 3.25 × 106 cells/mL. To permeabilize and track calcium uptake
the cells, the suspension was stirred in a 1 cm pathlength acrylic cuvette at 37 C with 40 µM
digitonin (DMSO) and 2 µM of Calcium Green 5N (Invitrogen, aqueous solution). A SLM
8100C steady-state fluorimeter (excitation=506 nm, emission=532 nm) was used to monitor
the fluorescence of the Calcium Green 5N dye. Calcium (starting with 7.5 µM boluses) was
added to test for mitochondrial calcium uptake inhibition. Compounds were added (5 µM),
after two calcium boluses were added to the solution to verify cellular action after a stable
emission intensity baseline was achieved. Alternatively the compounds can be incubated
before adding calcium boluses if cellular action was verified using a previous cuvette.
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C.4 Mitochondrial calcium uptake in isolated yeast mitochondria
Yeast mitochondria were reconstituted with the human components of the mitochondrial
calcium uniporter MCU and EMRE as previously reported366 in a yeast strain expressing
a mitochondrial matrix-targeted aequorin as an indicator of Ca2+ concentration.168,366 Ap-
proximately, 1 µg/well of isolated mitochondria was seeded into a white 96-well plate and
incubated in the presence of compounds (aqueous solutions) at varied concentration levels
for 5 min at room temperature. Ca2+-stimulated light signal was recorded at 469 nm every
0.1 s with a luminescence counter (MicroBeta2 LumiJET Microplate Counter, PerkinElmer).
Luminescence intensity was converted to calcium concentration as previously described.367
Plots of normalized calcium concentration, versus concentration of ruthenium complex gave
dose-response curves that were fit with the Hill Equation: y = A+ (B−A)x
n
kn+xn
.
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